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Abstract 
 
Phenobarbital (PB) is a prototype inducer of genes encoding drug metabolizing enzymes 
including the cytochromes P450 (CYPs). Additionally, phenobarbital was found to 
repress genes that encode enzymes involved in gluconeogenesis such as 
phosphoenolpyruvate carboxykinase (PEPCK). Constitutive androstane receptor (CAR) 
is known to play a fundamental role in the phenobarbital-mediated regulation of 
cytochromes P450 and in gluconegenesis in the liver. Phenobarbital was recently shown 
in our laboratory to activate a known inhibitor of hepatic glucose production, the energy 
sensor AMP-activated kinase (AMPK). In the present thesis, we investigated the role of 
AMPK in the phenobarbital-mediated inhibition of gluconeogenesis. Our experiments 
reveal that both CAR and AMPK are necessary to mediate the PB inhibitory effect on 
PEPCK mRNA expression. Furthermore, our study indicates that AMPK and CAR 
physically interact in this process. We speculate that once activated by PB, the CAR-
AMPK complex may prevent coactivators such as PGC-1α to interact with partners at the 
PEPCK promoter. However, overexpression of exogenous CAR dose-dependently 
increased PEPCK mRNA expression and its promoter activity in a human hepatoma cell 
line. The co-transfection of CAR with PGC-1α, a master regulator of PEPCK, clearly 
increases PEPCK promoter activity. Moreover, we show that the cotransfection of CAR 
and protein kinase A (PKA), a well established inducer of gluconeogenic pathways, dose 
dependently activates PEPCK. 
Our results also indicate that similarily to PEPCK, CAR mRNA expression is induced 
during fasting and in the absence of glucose. CAR also induces genes that encode for 
glucose transport during fasting. On the other hand, insulin represses CAR mRNA 
expression suggesting that CAR plays a significant role in the fasting-feeding transition. 
Finally, we demonstrate that CAR regulates the expression of genes encoding for of 
acetyl-CoA carboxylase (ACC), an enzyme known to be involved in the control of 
lipogenesis and beta oxidation of fatty acids. Altogether, these studies indicate that CAR 
is involved in the regulation of glucose and lipid metabolism and the regulation of its 
activity may be crucial to understand the molecular mechanisms that link drug 
metabolism to energy metabolism. 
  
Introduction 
 
Cytochromes P450 in drug metabolism 
 
We are daily exposed to various exogenous potentially harmful compounds. Fortunately, 
our organism possesses very sophisticated mechanisms to metabolize these toxic 
substances. In the liver, primary detoxification process occurs, where hydrophobic 
compounds are converted to more polar molecules to be further excreted into body fluids. 
This process is controlled by a whole arsenal of drug metabolizing enzymes including the 
cytochromes P450 (CYPs) which catalyze the so-called phase I in the detoxification 
process. In phase II and III, many other enzymes further modify these substances, which 
are then transported for excretion by urine faeces and bile [1]. 
CYPs are probably the biggest and the most studied drug metabolizing enzymes. In 
eukaryotic organisms, CYPS are essential and many different endogenous compounds 
have been identified to be substrate of these enzymes including steroids, bile acids, fatty 
acids, prostaglandins, leukotrienes, biogenic amines, and retinoids [2, 3]. Interestingly, 
CYPs are present from bacteria to humans. However, in higher animals the enzymes are 
membrane-bound and located in the endoplasmic reticulum or in the inner mitochondrial 
membrane. In most species, and in addition to their role in metabolizing endogenous 
compounds, some of these CYPs are important in the metabolism of various substrates 
such as drugs, carcinogens, food additives, pollutants, pesticides, or environmental 
chemicals [4]. Since CYPs play key roles in metabolizing pathways of a variety of 
compounds, their expression must be highly regulated. 
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Drug-mediated induction of cytochromes P450 
 
A common characteristic of CYPs is their relatively low basal expression in the absence 
of substrate and their highly elevated expression in the presence of their own substrates or 
other inducer compounds, a phenomenon called drug induction [4-6]. This process is 
tissue-specific, rapid, dose-dependent and reversible. In higher animals, it occurs mainly 
in the liver, in the intestine and to a lesser extent in kidney, lung and brain. More than 40 
years ago, CYPs increased concentration has been shown upon increases doses of the 
barbiturate phenobarbital (PB) treatment in rat livers. Those animals progressively 
adapted to PB due to enhanced drug metabolism clearance. In rat, smooth endoplasmic 
reticulum of hepatocytes was found to proliferate upon PB treatment [7, 8]. 
Altered expression of CYP genes has a major impact on drug effects including drug-drug 
interactions, drug toxicity, xenobiotic carcinogenicity and therefore contributes to 
clinically important interindividual variability in drug responses and hormonal disposal 
[9-13]. 
Many drugs and chemicals have the ability to induce their own metabolism by 
transcriptional activation of CYPs. Moreover, inducers can drastically alter the pattern of 
gene expression in the liver giving raise to pleiotropic hepatic responses. For instance, in 
a recent study, PB was shown to affect more than 100 genes in mouse livers [14].  
Drug-metabolizing enzymes mainly belong to the CYP1, CYP2, CYP3 and CYP4 
families and their prototypical inducers are classified in five classes: dioxin for the group 
of polyaromatic hydrocarbons inducing mainly CYP1As, PB-type inducers have a 
predominant effect on CYP2Bs, CYP3As and CYP2Cs subfamily genes, dexamethasone 
or rifampicin involved in CYP2Cs and CYPs3As induction, clofibrate acting on the 
CYP4As which metabolize fatty acids and ethanol that increases the activity of CYP2Es 
[15, 16]. 
The molecular mechanism of hydrocarbon induction of CYP1As by the polyaromatic 
hydrocarbon receptor (AhR) was elucidated already in the 1980s [17], whereas the 
scientific community had a hard time to figure out the mechanism of PB-type induction 
of CYPs due to several experimental limitations. Among them two contributed massively 
to the poor knowledge in this field. First, PB-type inducers bind with low affinity to their 
receptors, which made the discovery of the receptor very difficult; second, lack of cell 
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lines, which maintain PB-type responses constrained the use of either whole organs or 
primary preparation of hepatocytes in these studies. 
The first insights in the transcriptional regulation of CYPs came from a negative 
regulated element in the proximal promoter of P450 from BM-3 Bacillus megaterium [18, 
19]. Sequences homologous to this element referred to as Barbie Box were also found in 
proximal promoters of mammalian CYPs [20, 21]. Several proteins binding to the 
promoter were identified and shown to regulate the basal levels of expression and the 
tissue specific expression. However, a growing body of evidence suggested an important 
role of a distant enhancer element in drug regulation of CYPs. The first discovery of such 
regulatory sequence was made in 5’-flanking regions of the CYP2H1 gene in chicken 
embryo hepatocytes [22] and later in rat CYP2B2 [23] and mouse Cyp2b10 [24] gene. In 
the attempt to isolate small and well defined distal elements in CYP genes that are 
necessary for drug-mediated induction, the regulatory sequences found in the chicken 
CYP2H1, rat CYP2B2 and mouse Cyp2b10 were reduced to the minimal length still 
responsive to drugs. A 163-bp responsive element in the CYP2B2 [25] [26] as well as a 
264-bp in CYP2H1 [27] and a 51-bp in the cyp2b10 [28] were shown to be sufficient to 
mediate PB induction. Analysis of these sequences revealed the presence of putative 
hexamer half-sites suggesting for the first time that transcription factors may be involved 
in drug regulated expression of CYPs (discussed below). 
The pleiotropic effects of phenobarbital 
For many years, PB has been extensively used to treat epileptic patients, but the real 
impact of this drug has been underestimated. Several decades ago PB was shown to 
induce drug metabolism [29]. Since then, many different groups have described 
numerous other biological processes affected by PB. 
Tumour promotion 
One of the most disturbing effects of PB exposure is the development of liver tumours in 
rodents. Mice acutely treated with PB develop hepatomegaly, cellular hypertrophy and 
hyperplasia [30]. Moreover, in the early 70s PB was shown to promote hepatocellular 
carcinoma (HCC) [31]. However, in humans chronic PB treatment has never been shown 
to induce tumor promotion. This human resistance is probably due to many different 
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reasons, including shorter telomeres [32]. Indeed, telomerase-deficient mice are resistant 
to chemically induced hepatocarcinogenesis [33]. 
Steroids and thyroid metabolism 
Chronic treatment with PB is known to promote thyroid hypertrophy in humans and in 
rats [34, 35]. Levels of thyroid hormones (TH) are determined by a tight control of the 
balance between their synthesis, metabolism and secretion. Thyroid stimulating hormone 
(TSH) regulates synthesis of inactive tetraiodothyronine (T4). T4 is converted to the 
bioactive triiodothyronine (T3) by deiodinases in the peripheral target tissues, such as 
liver and kidney. Recently PB was shown to decrease the level of T4 in mice [36]. 
Bile acid metabolism 
Bile acids are the major products of cholesterol catabolism and, acting as physiological 
detergents, promotes intestinal absorption of dietary lipids. The levels of bile acids are 
regulated by the balance of synthesis and elimination. CYP7A1 is the rate-limiting 
enzyme of bile acid synthesis, while other enzymes are involved in transport and 
elimination [37] [38]. Accumulation of bile acid in the hepatocyte impairs liver function 
and causes intrahepatic cholestasis. Indeed, PB has been extensively used to treat pruritis, 
a side effect of elevated serum bile acids associated with cholestasis [39]. 
A recent study has suggested that PB represses CYP7A1 gene expression in mouse liver 
by interfering with the recruitment of hepatic nuclear factor 4α (HNF4α), an important 
transcription factor in CYP7A1 regulation [40]. Moreover, our group has demonstrated 
that PB represses chicken HNF4α transcript levels concomitant with a reduction in 
CYP7A1 expression [41]. However, mammalian HNF4α expression is not repressed by 
drugs. Altogether these results show that, besides the importance of HNF4alpha in 
CYP7A1 regulation in all species, birds and mammals use different signaling pathways to 
adjust CYP7A1 levels after exposure to xenobiotics. 
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Glucose metabolism 
Chronic PB treatment reduced plasma glucose levels in diabetic patients [42]. Hepatic 
gluconeogenic enzymes, such as phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pase) are repressed in PB-treated rats and mice [43, 44]. 
Interestingly, in the early 60s insulin was reported to repress drug metabolism [45]. 
Hepatic levels of CYP2B and CYP3A were increased in diabetic mice and rats and 
insulin treatment decreased them to normal levels [46] [47]. In support of these 
observations, Yoshida et al., showed that insulin blocks PB induction of CYP2B in rat 
primary hepatocytes in culture [48] [49]. These results suggest a strong link between drug 
metabolism and glucose homeostasis. Unfortunately, the molecular mechanisms by which 
insulin influences drug metabolism and the mechanisms by which PB affects hepatic 
glucose production remain unclear. This thesis approaches some of the remaining 
questions. 
Phosphorylation/dephosphorylation events in phenobarbital-
mediated induction of cytochromes P450 
Several experimental observations point to a role of phosphorylation and 
dephosphorylation events in the indirect mechanism of PB induction of CYPs. 
For many years it was assumed that PB induction requires de novo protein synthesis. 
However, evidence has accumulated which indicates that de novo protein synthesis is not 
required for PB induction. In fact, post-transcriptional modifications have been shown to 
regulate PB signalling in hepatocytes, i.e. protein kinases/phosphatases. 2-Aminopurine, 
a general inhibitor of serine/threonine protein kinases, blocked CYP2B1/2 induction in 
rat hepatocytes [50], and CYP2H1 and ALAS1 induction in chick embryo hepatocytes by 
PB [51]. Genistein, a tyrosine protein kinase inhibitor, also fully blocked Cyp2b10 
induction by PB in mouse hepatocytes [52]. However, other studies reported no effect of 
genistein on CYP2H or CYP2B induction by PB [51, 53, 54]. Elevated intracellular 
levels of cAMP resulted in a dramatic inhibition of PB-mediated induction of CYP2B1, 
CYP2B2 and CYP3A1 gene expression in primary cultures of rat hepatocytes [55] and of 
Cyp2b10 in mouse hepatocytes [56], suggesting an involvement of cAMP-dependent 
protein kinase A (PKA). In addition, elevation of intracellular cAMP by forskolin, an 
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adenylate cyclase activator, led to a dose-dependent repression of PB-inducible gene 
expression. Consequently, PKA may exert a negative role on CYP2B induction by PB. 
However, a study by Honkakoski et al. in primary mouse hepatocytes did not find any 
effect of forskolin and dibutyryl cAMP on Cyp2b10 inducibility by PB [57]. Moreover, 
no direct effect of PB on cAMP levels or PKA activity could be detected in mouse and rat 
hepatocytes [57, 58] and in avian LMH cells [27]. However, data obtained by the use of 
forskolin have to be interpreted with caution, because this PKA modulator is a ligand and 
activator of human and mouse PXR [59]. Other studies showed inhibition of Cyp2b10 
and Cyp3a11 induction by PB in mouse hepatocytes treated with the Ca2+/calmodulin-
dependent protein kinase inhibitor KN-62 or intracellular Ca2+ chelator BAPTA-AM 
[56]. In this regard, Yamamoto et al. blocked the TCPOBOB-mediated induction of 
Cyp2b10 in mouse hepatocytes by KN-62 [60]. Interestingly, this compound did not 
affect the nuclear translocation of CAR. Alternatively, okadaic acid, a potent inhibitor of 
serine/threonine phosphatases PP1 and PP2A, also fully prevented PB induction of 
CYP2B1/2B2 and Cyp2b10 in hepatocytes [61, 62]. Moreover, our group has pointed out 
a new target of PB in the cell. We showed that PB increases the activity of an energy 
sensor, AMP-activated kinase (AMPK). Indeed, this kinase is necessary to mediate the 
induction of CYPs by PB in human and in mouse livers [63, 64]. A growing body of 
evidence suggests that phosphorylation is involved in PB-mediated induction of CYPs. 
Nevertheless, further functional studies are required to elucidate the role of 
phosphorylation in this process.  
 
Nuclear receptors 
Cell-cell communication within an organism is necessary in all phases from 
embryogenesis to the coordination of all vital functions during the life span. 
Communication is assured by messenger molecules, which usually bind to membrane 
receptor or if they are lipophilic and small enough to cross the membrane, they often 
interact with members of the family of nuclear receptors, which act as transcription 
factors. This family is subdivided into three classes, the classical hormone receptors, the 
sensor receptors and the orphan nuclear receptors [65]. The endogenous ligands for the 
orphan nuclear receptors are not known, whereas the classical hormones receptors bind 
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molecules such as glucocorticoids, thyroid hormone, estrogen and retinoic acids, and are 
thus key factors in the endocrine homeostasis. The third class of “sensor” receptors bind 
endogenous compound such as fatty acids (peroxisome proliferators activated receptor, 
PPAR), oxysterols (liver X receptor, LXR), bile acids (farnesoid X receptor, FXR), or 
sense drugs and toxic levels of endobiotics (constitutive androstane receptor, CAR and 
pregnanes X receptor, PXR). These receptors are sensors of the metabolic state and 
responsible for the metabolic adaptation by responding to incoming dietary signals and 
metabolites generated in the organism. The hepatocyte nuclear factor 4α (HNF-4α) is also 
considered as a metabolic sensor because of its effects on glucose, fatty acids and 
cholesterol metabolism; however the question about its endogenous ligands is not 
completely solved. 
The NR family is ancient in its origin and was well diversified even before the 
arthropod/vertebrate split [66]. NRs control the activity of target genes directly by 
interacting as monomers, homodimers or heterodimers with the distal enhancer elements, 
located in the promoter of their target gene. Response elements (RE) consist of two 
hexamer core half-sites, with consensus AGG/TTCA, which are arranged as direct repeats 
(DRs), inverted repeats (IRs) or everted repeats (ERs) spaced by different numbers of 
nucleotides. The NRs that bind as monomers, usually bind to an extended half-site, the 
extension being rich in A and T [67-69]. 
The mechanisms by which the nuclear receptors can regulate the transcription of the 
target gene are currently under intensive investigation. In addition to direct contact to the 
transcriptional machinery, NRs enhance or inhibit transcription by recruiting coactivator 
and corepressor proteins. The ligand binding causes a conformational change in the 
receptor, which leads to the recruitment of coactivators or corepressors (Figure 1A). The 
role of the cofactors is to facilitate the communication between NRs, the basal 
transcriptional machinery and the chromatin environment. Because the NRs need to gain 
access to the DNA, which is wrapped around histones forming nucleosomes, they recruit 
coactivators which stabilize the chromatin structure by several mechanisms including 
histone acetylation. On the other hand, in the absence of ligands or in the presence of 
antagonists, the corepressors recruit the histone deacetylase, which inhibits transcription 
[70-74]. 
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Members of the nuclear receptor superfamily share structural and functional domains 
such as a highly conserved zinc finger DNA binding domain (DBD or C domain), which 
allows binding of the receptor to DNA, and a C-terminal ligand binding domain (LBD or 
E domain), which interacts with the ligand and allows dimerization. Other less conserved 
regions are the N-terminal region (A/B domain), a hinge region (D domain) between the 
DBD and the LBD, and a C-terminal region (F domain) in some receptors (Figure 1) [75, 
76].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Nuclear receptors 
 
 
Pregnane X receptor 
PXR, alternatively called steroid and xenobiotic receptor, was discovered in mice and 
humans by three independent groups [77-80]. This receptor is activated by a multitude of 
very different drugs due to its extraordinarily large and flexible ligand binding pocket. 
Amino acid sequence comparison of LBD of different PXR orthologs revealed an 
unusual high divergence [81]. This divergence explains the species differences observed 
in induction of CYPs by PXR. For example, changing four amino acids of mouse PXR 
into the corresponding amino acids of the human counterpart led to a typical human 
activation pattern [82]. Similarly, PXR knockout mice that express the human PXR 
exhibit a typical human response to different inducers [83]. The flexibility and relative 
lack of specific binding interactions is supported by the observation that even the potent 
 
 
 
A. 
B. 
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inducer SR12813 can bind to PXR in three distinct orientations [82]. The analysis of the 
binding site in PXR target genes indicates that this receptor is rather flexible in its 
binding specificity. Among others, binding and activation of DR-3, DR-4, ER-6, ER-8 
and IR-0 were reported [78, 79, 84, 85]. PXR is found normally in the nucleus, where it is 
activated by ligand binding [86]. However, PXR was recently proposed to accumulate 
also in the cytoplasm in complex with Hsp90 and CCRP by overexpression of the latter 
[87]. The first identified targets of PXR were CYP3A1 and CYP3A4 in rat and human, 
respectively [79, 80, 83]. Later, other genes were shown to be regulated by PXR, such as 
CYP2Bs, MDR1, MRP2, OATP2 among others (for a recent review, see [88, 89]). 
In PXR knockout mice, induction of Cyp3a11 by PCN, which is a typical PXR inducer, is 
impaired. However, Cyp3a11 can still be activated by PB via CAR [83, 90], indicating 
that CAR may cross-regulate Cyp3a11 as suggested by DNA binding and transfection 
experiments.  
Constitutive androstane receptor 
The PB-responsive unit (PBRU) in the CYP2B genes flanking region is composed by one 
DR-4 repeat used in affinity purification for isolation of proteins binding to this sequence 
and thereby mediating drug induction. This approach led to the observation that murine 
CAR binds to Cyp2b10 [91]. Like PXR, CAR shows high species-specific divergence in 
amino acid sequence in the LBD. Moreover, low-affinity ligands are typical for CAR, 
although its ligand binding pocket is smaller in comparison to PXR. CAR recognizes 
preferably DR-4 and DR-5 repeats [92, 93], but DR-1, ER-6 and ER-8 can also serve as 
CAR binding sites, too [40, 94, 95]. Different activation mechanisms of CAR were 
reported, which do not require the binding of the inducer to the receptor. Although CAR 
can be directly activated by 1, 4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) 
binding, PB and other inducers were never shown to bind to the receptor. In contrast to 
PXR, CAR is usually located in the cytoplasm and is transferred to the nucleus by ligand 
binding or by an indirect mechanism, which does not require receptor binding. Initial 
reports described CAR as a constitutively active receptor [92, 93, 96] since transiently 
transfection of CAR in HepG2 cells elicited high basal activity of Cyp2b10 or CYP2B6 
PBRU in reporter gene assays [95]. In these cells CAR is already located in the nucleus 
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and its activity can be inhibited by certain androstanols, which act as inverse agonists 
(mouse CAR). 
In primary cultures of hepatocytes and in liver, CAR is located in the cytoplasm. PB was 
shown to activate CAR by an indirect mechanism leading to its cytosolic-nuclear 
translocation [56]. This process is controlled by protein dephosphorylation events since 
the protein phosphatase inhibitor okadaic acid inhibits nuclear CAR transfer. In addition, 
translocation appears to be mediated by a xenobiotics response signal (XRS), which is 
located in the C-terminal region of CAR [97]. This xenosensor is retained in the 
cytoplasm under normal conditions in a complex of several proteins of which only a few 
are known. Heat shock protein 90 (Hsp90) and cytoplasmic CAR retention protein 
(CCRP) were recently described to interact with CAR in the cytoplasm, whereas protein 
phosphatase 2A (PP2A) was shown to be recruited by PB treatment [98, 99]. If this 
cytosolic complex retains CAR in the cytoplasm and/or protects it from degradation is 
still not known. Experiments using calcium/calmodulin-dependent protein kinase 
(CaMK) inhibitors revealed that once CAR is in the nucleus, its activity is modulated by 
protein phosphorylation events [100]. 
The role of the xenosensors pregnane X receptor and constitutive 
androstane receptor in drug induction  
In the last years, unique roles for nuclear receptors in the regulation of CYP enzymes 
emerged. In particular, CAR and PXR, which regulate the expression of CYP2B and 
CYP3A genes, respectively [101, 102]. PXR and CAR are abundantly expressed in liver 
and intestine, the places where drug metabolism occurs. They bind to DNA as 
heterodimers with RXR, which is the heterodimerization partner of several other sensor 
receptors (LXR, FXR, and PPAR). 
 
CAR mediates PB effects  
As previously mentioned, pleiotropic effects in the liver were observed by treatment with 
PB, such as liver hypertrophy or liver tumor promotion by long-term treatment, both of 
which are absent in CAR-null mice in comparison to wild-type mice [30, 103, 104]. 
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Thus, CAR is not only responsible for the transcriptional up-regulation of CYP genes 
caused by PB, but also for other hepatic responses. Despite much progress in 
understanding CAR-dependent hepatic responses, the molecular mechanisms of CAR-
mediated signal transduction remains enigmatic. 
CAR and drug metabolism 
In CAR knockout mice induction of Cyp2b10 by TCPOBOP and PB in the liver was 
absent, establishing a fundamental role for CAR in this response. Furthermore, induction 
of other CAR target genes was impaired in the liver of knockout mice [14, 30, 105, 106]. 
A recent cDNA microarray analysis showed that, upon PB CAR up-regulates a set of 
genes that encode CYP2B, CYP2C, CYP3A, NADPH-cytochrome P450 reductase, 
sulfotransferases, glucuronyltransferases and glutathione S-transfereases [14]. In addition 
to these phase I and II drug-metabolizing enzymes, CAR also regulates genes encoding 
transporters such as Mrp2 and Mrp4 [94]. As CAR can be activated by many different 
drug and xenobiotics, this receptor may be a central gatekeeper against toxicity and 
carcinogenicity in the liver. [60].  
CAR and bilirubinemia  
Because all the enzymes and transporters up-regulated by CAR are also involved in the 
metabolism of endobiotics secretion, the protective role of CAR is also extended to 
endogenous compounds. Bilirubin is the catabolic byproduct of heme derived from β-
globin and cytochromes. It is one of the most toxic endobiotic compounds. Its 
accumulation causes hyperbilirubinemia which can leads to neuronal diseases. However, 
in a non pathological state, UGT1A1 gene encodes bilirubin UDP-
glucuronosyltrasnferase that catalyzes conjugation of bilirubin with glucuronic acid. This 
conjugation reaction followed by transport by organic anion transporting polypeptide 2 
(OATP2) and multidrug resistance-associated protein 2 (MRP2) constitutes the major 
bilirubin detoxification pathway. The group of Masahiko Negishi found that CAR 
regulates the PB-induced transcription of the UGTA1 gene [107]. In addition CAR also 
mediates the PB induction of glutathione S-transferase A1/A2 and the transporters OATP 
and MRP2 to increase bilirubin clearance [108]. 
         
 19 
CAR and tumor promotion 
The potential of human CAR as tumor promoter cannot be ruled out, because intriguing 
data in rodents suggest that not all mouse strains are susceptible to hepatocellular 
carcinoma (HCC) promotion by PB. Because CAR is activated by PB it was logical to 
examine whether CAR is involved in PB promotion of HCC. In two recent publications, 
CAR-null mice (CARKO) were used to investigate the role of CAR in the development 
of HCC. The data of the first publication present experimental evidence that CAR has an 
essential role in the liver tumor promotion induced by TCPOBOP, another strong tumor 
promoter [103, 104]. In the second study, liver tumors were initiated by a single injection 
of a typical genetoxic carcinogen diethylnitrosamine (DEN) in CAR wild type and CAR 
KO mice, subjected to chronic treatment with PB. After 35 weeks of PB treatment, HCC 
only developed in wild type mice. After 50 weeks, all wild type mice died of liver 
tumors, whereas CAR KO stayed protected from tumor or death [103]. 
Moreover, a locus on chromosome 1 associated to the HCC formation susceptibility is 
amplified in more than half of human HCC samples. Thus, a short and transient 
hepatomegalic response promotes xenobiotic clearance, but chronic CAR activation can 
create a tumorigenic environment. For full understanding, further studies on the 
relationship of human CAR to HCC are necessary. 
CAR and thyroid function 
As previously mentioned, the chronic treatment with PB or PB-like inducers is known to 
promote thyroid hypertrophy in humans [35] and to decrease the level of total serum T4, 
thus decreasing the metabolic rate. Obese individuals trying to lose weight have to face 
with the homeostatic resistance mechanisms that operate to resist weight loss. In fact, 
during periods of reduced caloric intake or fasting the level of thyroid hormones and 
consequently the basal metabolic rate are decreased, which results in low energy 
expenditure and low caloric loss. It is well established that CAR target genes, such as 
UGT and SULT, which can metabolize thyroid hormones, are up-regulated during fasting 
[109]. It was thus reasonable to test if CAR plays a role in these events. Recent studies 
reported that CAR is required for the increased expression of sulfo- and glucuronyl-
transferases that accelerate the clearance of thyroid hormones, in turn resulting in 
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decreased serum T4 levels. Indeed, fasted CAR-null mice under calorie-restricted diet for 
12 weeks lost more than twice as much weight as the wild type animals [36, 109]. These 
studies indicate that CAR contributes to the homeostatic resistance to weight loss, and 
thus its inverse agonists might be useful in the treatment of obesity. 
 
CAR and glucose homeostasis 
As previously mentioned PB has been shown to lower glyceamia in diabetic patients.  
Moreover, it was found that CAR regulates the PB-induced repression of PEPCK [14]. 
Kodama et al. recently showed that CAR and forkhead transcription factor, FOXO1, 
interact, thereby coregulating reciprocally CAR and FOXO1 target genes and affecting 
both drug metabolism and gluconeogenesis [110]. However these datas have to be 
interpreted with caution because no in vivo evidence supports these findings. The 
discrepancy of these results with our study will be discussed below. 
Glucose metabolism 
Few physiological parameters are more tightly and acutely regulated in humans than 
blood glucose concentration. Elevated glucose levels are rapidly returned to normal (5–
6 mM) even after huge caloric ingestions, and they are maintained at only slightly lower 
levels during long-term starvation. Such control prevents severe dysfunctions such as loss 
of consciousness due to hypoglycemia and toxicity to peripheral tissues in response to the 
chronic hyperglycemia of diabetes. 
Pancreas 
High glucose levels influence gene expression either directly or through the stimulation 
of insulin production by the β-cells. Pro-insulin is synthesized in the β-cells of the 
pancreatic Langerhans islets and is cleaved by proconvertases into insulin and peptide C. 
Insulin is stored in secretory vesicles, and its secretion is directly linked to a sensing 
glucose-sensing mechanism availability via an increase in the intracellular ATP/ADP 
ratio that correlates with the entry and metabolism of glucose in the β-cells [111]. The 
entry of glucose into the β -cells requires a glucose transporter, Glut2 in rodents but Glut1 
rather than Glut2 in humans [112], whose expression and membrane localization are 
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independent of glucose or insulin signalling. The posttranscriptional control of insulin 
expression and processing, as well as the control over the secretory mechanism, which are 
dependent on glucose sensing, are key features of the regulation of insulin signalling.  
On the other hand, in response to stressful stimuli, such as hypoglycemia, glucagon is 
processed from a large precursor, proglucagon, in pancreatic alpha-cells. Glucagon 
primarily acts on liver to initiate glycogenolysis and gluconeogenesis, resulting in a rapid 
increase in endogenous production of glucose. With longer stimulation, glucagon action 
at the liver results in a glucose-sparing activation of free fatty acid oxidation and 
production of ketones (Figure 2). During hypoglycemia, glucagon secretion is clearly a 
protective feed-back, defending the organism against damaging effects of low glucose in 
brain and nerves (neuroglycopenia). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Regulations of blood glucose 
Glyceamia is permanently regulated by the glucagon/insulin ratio. In the post-absorptive 
state, insulin promotes glucose uptake and glycogen synthesis in muscles, whereas during 
fasting glucagon induces glycogenelysis, hepatic glucose production and ketogenesis in 
sustained fasting. 
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Muscle 
The major cellular mechanism that diminishes blood glucose when carbohydrates are 
ingested is insulin-stimulated glucose transport into skeletal muscle. Skeletal muscle both 
stores glucose as glycogen and oxidizes it to produce energy following the transport step. 
The principal glucose transporter protein that mediates this uptake is GLUT4, which 
plays a key role in regulating whole body glucose homeostasis [113]. Early studies using 
indirect calorimetry in combination with femoral vein catheterization and the euglycemic-
hyperinsulinemic clamp suggested that nonoxidative glucose metabolism was the major 
pathway for glucose disposal in healthy subjects [114, 115]. These data suggested that 
during a hyperglycemic-hyperinsulinemic clamp, skeletal muscle accounts for the vast 
majority of glucose uptake in normal humans and that over 80% of this glucose is then 
stored as muscle glycogen [116]. Moreover, during fasting, the muscle provides lactate, 
pyruvate and amino acids from protein catabolism to the liver. In the hepatocytes, these 
compounds will then be used as gluconeogenic substrate.  
Adipose tissue  
Traditionally, the major function of adipose tissue is considered to be energy storage. 
When fuel is required, (e.g. during periods of fasting, starvation, or exercise) free fatty 
acids (FFAs) are released from adipose triglyceride stores into the circulation by lipolysis 
and oxidized, primarily by skeletal muscle, to provide energy. However, a whole arsenal 
of evidence suggests that adipose tissue also plays an important part in other 
physiological processes; for example, as an endocrine organ. Adipocytes secrete proteins 
involved in a variety of functions, including glucose homeostasis. Early studies 
determined that adipose tissue accounts for only a fraction of glucose disposal after a 
meal (about 10–15%), with most of the rest taken up by muscle [117]. Nonetheless, it 
was equally clear that alterations in adiposity have profound implications for glucose 
homeostasis; too much fat (obesity) and too little fat (lipodystrophy) are both associated 
with insulin resistance and hyperglycemia. Moreover, Adipocytes secrete proteins with 
anti-diabetic action including leptin, adiponectin, omentin and visfatin, whereas other 
factors tend to raise blood glucose, such as  resistin and TNF-α [118] 
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Liver 
The liver plays a unique role in controlling carbohydrate metabolism by maintaining 
glucose concentrations in a normal range, expressing a number of enzymes that are 
alternatively turned on or off depending on blood glucose levels. In the post-absorptive 
state, 75 % of the total glucose disposal occurs in insulin-independent tissues, 
approximately 50 % in the brain and 25 % in the splanchnic area including the liver 
[119]. Glucose utilization, which averages approximately 2.0 mg/kg/min, is exactly 
balanced with the production of glucose from the liver. Gluconeogenesis accounts for a 
substantial fraction (64 %) of total glucose production even during the first 22 hours of a 
fast in humans [120]. In the post-prandial period, the liver takes up a portion of ingested 
carbohydrates to restore glycogen stores, however the majority (approximately 80-85 %) 
of glucose disposal occurs in muscle tissue. After glucose enters a cell it can be either 
converted to glycogen (mainly in muscles (70 %)), or engaged in the pentose phosphate 
pathway or enters the glycolytic pathway. In addition, the liver is the principal site of 
insulin degradation, eliminating up to 70 % of the portal insulin [121].  
Upon entry into the cells, glucose is phosphorylated to Glucose 6-Phosphate (G6P) by 
Glucokinase (GK) in hepatocytes and by hexokinase in all other cells [122]. This step is 
required for glucose to undergo glycolysis, be used in the glycogen synthesis pathway, or 
enter the pentose phosphate pathway (Figure 2). This first metabolic transformation of 
glucose is also required for generating the signal that acts in transcriptional regulation. 
Some reports suggest that G6P itself might be the signal for glucose uptake in the cell 
[123]. Alternatively, other metabolites such as xylitol produced by the pentose phosphate 
pathway or intermediates of the hexosamine biosynthetic pathway might also act in 
tissue-specific regulations [124].  
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        From Roden et al. [117] 
Figure 3:  The fate of glucose in the hepatocyte. 1glucokinase, 2phosphofructo-1-kinase, 3pyruvate 
kinase, 4phosphoenolpyruvate carboxykinase (PEPCK), 5fructose-1,6-biphosphatase, 6glycogen synthase, 
7glycogen phosphorylase, 8glucose-6-phosphatase. 
Glucose homeostasis 
Metabolic role of gluconeogenesis 
Gluconeogenesis provides glucose to the tissues of the body in the fasted state when 
dietary carbohydrates are not available, by formation of glucose from noncarbohydrate 
sources. The gluconeogenic process clears metabolic products, such as lactate and amino 
acids from protein catabolism produced by muscle from circulation and erythrocytes as 
well as glycerol produced by adipose tissue. The regulation of endogenous glucose 
production is crucial to the control of blood glucose concentrations, and the liver and 
kidney are the principal organs responsible for gluconeogenesis. 
Many of the enzymes of glycolysis and gluconeogenesis are shared, including those from 
phosphoenolpyruvate to fructose 1,6-diphosphate (Figure 2). In liver, glucose-6-
phosphatase catalyzes the rate-limiting step of gluconeogenesis. However, for 
gluconeogenesis to occur, the enzymes pyruvate carboxylase (PC), phosphoenol pyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) must be present and can 
limit flux through the gluconeogenic pathway [125]. 
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PEPCK 
Metabolic role of PEPCK 
Cytosolic form of phosphoenol pyruvate carboxykinase (PEPCK-C) (EC 4.1.1.32) is a 
key enzyme in the synthesis of glucose in the liver and kidney  [126]. In fact, the gene for 
PEPCK-C has become a marker gene for hepatic glucose output during fasting or in 
diabetes, or where the mechanism of action of hormones, transcription factors, or drugs 
of virtually every category is being assessed. However, PEPCK gene expression also 
occurs in tissues that do not make glucose, such as white and brown adipose tissue, and 
tissues where its role is unknown, such as: lung, mammary gland during lactation, 
skeletal muscle and the pancreas [127]. Despite the general lack of attention to the 
metabolic role of PEPCK in these tissues, there is a growing body of evidence regarding 
the alternative biological role for PEPCK in tissues other than the liver. In white [128] 
and brown adipose tissue [129], for example, PEPCK-C has been shown to participate in 
an abbreviate version of gluconeogenesis, termed glyceroneogenesis, a process that 
generates 3-phosphoglycerol from pyruvate and its precursors.  
In both liver and kidney various factors increase PEPCK transcription, including 
glucagon, glucocorticoids and thyroid hormone, whereas insulin inhibits this process. 
 
Regulation of PEPCK by the insulin/glucagon ratio 
In mammals glycaemia is controlled by tight regulated ration between glucagon and 
insulin. Indeed, in healthy animals, a decrease in plasma glucose results in the release of 
glucagon by pancreatic α-cells and glucocortioids by the adrenal gland. These hormones 
both increase the rate of PEPCK gene transcription. The released glucagon, reaches the 
liver by the portal vein and bind to a protein G coupled receptor to induce the cAMP 
pathway. The glucagon-induced production of intracellular cAMP activates protein 
kinase A (PKA). Roesler and colleagues have developed a model for the cAMP control of 
PEPCK-C gene transcription that involves a cAMP regulatory unit (CRU), which 
encompasses five CREs that have been described in the PEPCK-C gene promoter [130]. 
Since a number of transcription factors can bind to these sites in the CRU (see above for 
details), and all are present in the liver, their specific interaction on the promoter is 
considered as a critical element in determining the response of the PEPCK-C gene to 
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changes in the concentration of hepatic cAMP. However, the most important factor that 
mediates the cAMP response on endogenous glucose production (EGP) is the cAMP 
Response Element Binding protein (CREB). This transcription factor is phosphorylated 
by PKA, thereby leading to its binding to the PEPCK promoter.  
Glucocorticoids play a fundamental role in the maintenance of energy homeostasis in 
mammals. The removal of the adrenals severely compromises the ability of animals to 
withstand fasting and greatly diminishes the symptoms that are characteristic of diabetes, 
such as an elevated concentration of blood glucose. A key aspect of this response is the 
control of PEPCK-C gene transcription by glucocorticoids in several target tissues. 
Glucocorticoids stimulate transcription of genes in the liver that leads to the elevated 
level of hepatic glucose output noted during fasting. The concept of a large and complex 
Glucocorticoid Response Unit (GRU) was introduced by Granner and colleagues [131, 
132]. They first described the existence of a GRU in the PEPCK-C gene promoter, using 
rat hepatoma cells, and then characterized this unit using a relatively short segment of the 
PEPCK-C gene promoter (-600 to +68) [133]. The GRU co-ordinates the hormonal 
response of the PEPCK-C gene to glucocorticoids and interacts with the CRU to mediate 
the cAMP control of gene transcription. Altogether, these datas suggest a cooperative 
action of glucagon and glucocorticoids on PEPCK gene transcription. 
High plasma glucose stimulates insulin secretion and insulin will inhibit the action of 
glucagon and glucocorticoids in a dominant fashion [133-136]. The mechanisms 
responsible for the regulation of PEPCK-C gene transcription by insulin have been a 
major area of interest almost since the discovery of the enzyme in 1953 [137] and the 
realization that it was a critical step in hepatic glucose output in mammals. In 1963, 
Shrago and colleagues [138] published the first systematic analysis of the regulation of 
PEPCK-C gene expression by hormones, including insulin. They demonstrated that the 
injection of insulin into diabetic rats caused a decrease in the activity of hepatic PEPCK-
C to below basal levels. Latter on, The isolation and characterization of the gene for 
PEPCK-C provided the opportunity to directly study the mechanisms involved in the 
effect of insulin on PEPCK-C gene transcription. Soon after the isolation of the gene, it 
was demonstrated, using "run off" transcription assays, that insulin decreased the rate of 
PEPCK-C gene transcription in hepatoma cells [139] and in the livers of diabetic rats 
[140]. Magnuson and coworkers reported that insulin blocked the induction of 
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transcription from the PEPCK-C gene promoter (+69 to -2100) by dexamethasone and 
cAMP in H4IIE hepatoma cells [141]. An insulin response element (IRE) was later 
mapped at -416 to -407 in the PEPCK-C gene promoter. When this putative IRE was 
mutated, transcription from the PEPCK-C gene promoter in hepatoma cells was reduced 
by 50% [142]. This IRE lies within the glucocorticoid regulatory unit (GRU), 
overlapping an Accessory Factor binding region (AF2) that is required for glucocorticoid 
stimulation of PEPCK-C gene transcription (Figure 3). 
 
Partial anatomy of the PEPCK gene promoter 
The sequence of the PEPCK gene promoter from the rat [143], human [144] and mouse 
[145] have been described. Interestingly, the sequence of these three mammalian species 
share more than 95% of similarity from the start site of transcription to -1500. The 
regulatory elements responsible for the dietary and hormonal control of PEPCK-C gene 
transcription in the liver that have been studied to date bind within a region between -
1500 and +73 of the PEPCK promoter. This part of the promoter can be arbitrarily 
divided into three regions based on the clustering of regulatory elements (Figure 4) and 
the functional role of the binding sites in these regions.  
The Region 1 contains the CRE and an adjacent NF-1 site (P1) (Figure 3). Mutation of 
the CRE markedly reduces the cAMP responsiveness of the PEPCK gene promoter in the 
livers of transgenic mice [136], whereas a mutation of the NF-1 site causes a marked 
increase in the level of basal gene transcription [146, 147]. The CRE from the PEPCK-C 
gene promoter binds transcription factors, including CREB [148], CREM [149], C/EBPα 
[130], C/EBPβ [150] and others. 
In addition the several sites which have been shown to be critical for the transcription of 
the PEPCK gene in the kidney, region 2 contains a C/EBP binding domain, termed P3(I) 
[130, 151]. The C/EBP binding site at P3(I) is required for the full transcriptional 
responsiveness of the promoter to cAMP [136] and for the liver-specific expression of the 
PEPCK-C gene [127] (figure 4). 
Region 3 is probably the most studied segment of the PEPCK gene promoter. It contains 
the Glucocorticoids Regulatory Unit (GRU) which conveys the glucorticoids-mediated 
induction of PEPCK. The GRU was originally mapped between -321 to -455 of the 
PEPCK gene promoter [133, 152] but recent studies have demonstrated that it extends to 
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-1500 [153]. The AF1 site binds the hepatic-enriched orphan receptors HNF-4α [154], 
COUP-TFII [155], PPARγ [156], the retinoic acid receptorg α (RARα) [157] and retinoid 
X receptor α (RXR α) [158]. The AF2 site binds members of the Forkhead family 
including HNF-3β (Foxo2a) and the phosphorylated form of Foxo1 [159]. The deletion of 
this site results in the inhibition of the diabetes-induced increase of PEPCK gene 
transcription in the livers of transgenic mice and renders the PEPCK gene promoter 
refractory to induction by glucocorticoids [160]. The AF3 site binds the thyroid hormone 
receptor [161, 162] and overlaps a SREBP-1c binding domain on the PEPCK-C gene 
promoter [163]. There are two additional upstream binding sites in the extended GRU 
that we have termed distal AF1 (dAF1) and distal AF2 (dAF2) that are required for 
optimal response of the hepatic gene promoter to. The dAF1 (a PPARγ 2 binding site) 
binds PPAR/RXR and HNF4α and is required for the expression of the gene for PEPCK-
C in adipose tissue. Finally, there are also two SREBP-1c binding domains in this region 
of the PEPCK-C gene promoter, at -322 and -590, that are both potentially involved in 
the insulin inhibition of PEPCK-C gene transcription. The regulation of PEPCK by 
insulin will be discussed latter. 
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Figure 4:  A diagram of the PEPCK-C promoter showing the transcription factors and co-
activators that regulate the transcription of this gene. 
 
CREB = cAMP Regulatory Element Binding Protein; ATF3 = Activating Transcription Factor 3; COUP-
TF = Chicken Ovalbumin Upstream Promoter-Transcription Factor; PPARγ 2 = Peroxisome Proliferator-
Activated Receptorγ 2; SREBP-1 = Sterol Regulatory Element Binding Protein; HNF = Hepatic Nuclear 
Factor; GRU = Glucocorticoid Regulatory Unit; T3R, Thyroid Hormone Receptor; C/EBP = 
CAAT/Enhance Binding Protein; NF1 = Nuclear Factor 1; CREM = cAMP Regulatory Element Modifier; 
CBP/p300 = CREB Binding Protein/p300; PGC-1α = Peroxisome Proliferator-Activated Receptor 
Coactivator 1α; SRC-1 = Sterol Receptor Coactivator-1; RAR = Retinoic Acid Receptor; AF1 = Accessory 
Factor 1; AF2 = Accessory Factor 2; dAF1 = distal Accessory Factor 1; dAF2 = distal Accessory Factor 2; 
TRE = Thyroid Hormone Regulatory Element; Pol II = RNA polymerase II; GRE = Glucocorticoid 
Regulatory Element; CRE = cAMP Regulatory Element; P1, P2, P3(I). P3(II) and P4 are protein binding 
sites 
 
Regulation of PEPCK by co-factors 
Several transcriptional co-activators control PEPCK-C gene transcription; these include 
CREB Binding Protein (CBP) [147], sterol receptor co-activator 1 (SRC-1) [164] and 
PPARγ co-activator-1a (PGC-1α) [159]. CBP interacts with NF-1 [147], C/EBPβ and 
with SREBP-1c [165] to inhibit PEPCK-C gene transcription. Some reports suggested 
that SRC-1 interacts with HNF-4α, COUP-TFII and with HNF-3β, all of which are 
required for the maximal induction of PEPCK-C gene transcription by glucocorticoids 
and that the recruitment of SRC-1 is part of a transcriptional complex with CBP. PGC-1α 
coordinates the control of transcription of genes in the gluconeogenic pathway (PEPCK-
C and G-6-Pase) [166]. Glucagon induces the levels of PGC-1α mRNA, and over-
expression of PGC-1α stimulates transcription of the gene for PEPCK-C [166]. It is likely 
that PGC-1α is involved in coordinating the transcriptional response of hepatic PEPCK-C 
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to inductive stimuli, such as occurs during fasting. PGC-1α has also been proposed to be 
involved, together with Foxo-1 and HNF-4α, in the insulin-regulated inhibition of 
PEPCK-C gene transcription [159].  
AMP-Activated Protein Kinase 
The AMP-activated protein kinase (AMPK) is a ubiquitously expressed metabolic-stress-
sensing protein kinase that regulates metabolism in response to energy demand and 
supply by directly phosphorylating rate-limiting enzymes in metabolic pathways as well 
as controlling gene and protein expression. If the energy stock decreases, AMP/ATP ratio 
increases followed by activation of AMPK which subsequently turns off ATP-consuming 
pathways such as fatty acid, triglycerides and cholesterol synthesis as well as protein 
synthesis and transcription, and switches on catabolic pathways such as glycolysis and 
fatty acid oxidation (Figure 5). AMPK activity is activated by a wide array of metabolic 
stresses, including hypoxia, ischemia, and oxidative and hyperosmotic stresses. 
Furthermore, exercise and glucose deprivation also activate AMPK, which suggests a role 
in exercise adaptations and pancreatic β-cell function (reviewed in [167]). 
AMPK is a heterotrimeric enzyme that has been highly conserved throughout evolution 
as homologues of all three subunits that have been identified in plants, yeast, nematodes, 
flies and mammals [168, 169]. AMPKα is the catalytic subunit, which has to be 
phosphorylated by upstream kinases to be activated. β and   γ are regulatory subunits, 
necessary for catalytic function and stability of the kinase. The β subunit acts as a 
targeting scaffold, whereas the γ subunit was shown to bind AMP.  
Recent data showed that high cellular glycogen represses AMPK activation in muscle in 
vivo [170, 171], suggesting that AMPK may regulates cellular glycogen content. 
Supporting this thesis, AMPK β subunits contain glycogen binding domains that could 
associate AMPK to glycogen metabolism in overexpression studies [172]. 
To date three AMPK upstream kinases were identified, LKB1, CaMKK α and CaMKK β, 
which by phosphorylation of threonine172 of AMPK α subunit activate the kinase in cells 
and in vivo [167]. LKB1 is ubiquitously expressed and was shown to be required for 
activation of AMPK in response to AMP/ATP ratio changes, both in cultured cells and in 
vivo [173, 174]. In contrast, increases in AMP do not stimulate phosphorylation of 
Thr172 by the CaMKKs, which is triggered instead by a rise in Ca2+ [175-177]. CaMKKs 
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are mainly expressed in neural tissue; therefore their role in AMPK regulation in other 
tissue is not clear. 
Much of the previous work on AMPK was focused on its effects on energy homeostasis 
within individual cells. However, recent results suggest that AMPK might affect whole-
body energy metabolism by its activation by cytokines such as adiponectin and leptin, 
[178, 179], muscle contraction [180, 181] and by its regulation of insulin secretion in 
pancreatic β-cells [182].  
 
from [183] 
 
Figure 5:  Role of AMPK in the regulation of whole-body glucose homeostasis. 
 
Activation of AMPK turns on ATP-generating processes, while switching off ATP-consuming processes. 
In skeletal muscle, acute activation of AMPK increases glucose uptake and lipid oxidation, while chronic 
activation of AMPK is associated with mitochondrial biogenesis. Activation of AMPK inhibits glucose and 
lipid synthesis in the liver but increases lipid oxidation. Lipolysis and lipogenesis in adipose tissue are also 
reduced by AMPK activation 
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Aims  
The aims of the present thesis are to clarify the molecular mechanisms by which 
phenobarbital regulates gluconeogenesis and to explore the role of CAR and AMPK in 
this process. Particularly, we investigated the role of CAR during fasting and its diverse 
effect on PEPCK promoter activation. Finally, we studied the complex interplay between 
CAR, AMPK and PGC-1α. The specific aims of this thesis can be divided into four parts: 
 
Part I 
Study of CAR mRNA expression and its target genes during fasting and in the absence of 
glucose in a mouse hepatoma cell line. 
 
Part II 
In vitro investigations of the role of CAR in the regulation of the PEPCK gene. 
 
Part III 
Study of the impact of fasting and high carbohydrate diet in transgenic mice in which 
CAR has been deleted. 
 
Part IV 
Investigations of the role of CAR in the regulation of AMPK expression in primary 
mouse hepatocytes. 
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Results 
CAR as a glucose sensor ? 
Animal studies reveal that fasting and caloric restriction produce increased activity of 
specific metabolic pathways involved in resistance to weight loss in liver. Evidence 
suggests that this phenomenon may in part occur through the action of the constitutive 
androstane receptor. However, currently, the precise molecular mechanisms that activate 
CAR during fasting are unknown and the role of CAR in the regulation of weight remains 
controversial. A recent study show that fasting coordinately induces expression of genes 
encoding PGC-1α, Cyp2b10, Ugt1a1, sulfotransferase Sult2a1, and organic anion-
transporting polypeptide 2 (Oatp2), all CAR  target genes mouse liver [184]. In the next 
section, we described experiments showing that, besides the induced CAR mRNA levels 
during fasting; CAR may also be involved in the regulation of glucose homeostasis. 
 
CAR mRNA is induced by fasting and glucose depletion. 
The expression of CAR (Figure 1.1A) and PEPCK (Figure 1.1B) increased following a 
16 hours fasting period. Interestingly, the induction of both CAR and PEPCK is 
significantly reduced in the PB-treated animals. This result confirms that, in liver PEPCK 
is repressed by phenobarbital. However the repression of CAR is more intriguing 
especially because CAR has been previously shown to mediate PB repression on PEPCK 
[185].  In order to point out the molecular mechanism by which CAR expression is 
induced during fasting, we used a mouse hepatoma cell line (mAT3F). This cell line is 
very interesting because it has been previously described as a glucose-responsive system 
[186]. In fact, we were able to induce PEPCK (Figure 1.1D) and CAR (Figure 1.1C) in 
mAT3F cells cultured in glucose free medium for 48H. To allow gluconeogenesis to 
occur, we supplemented the medium with lactate and pyruvate (Cf material and 
methods). Surprisingly, phenobarbital induced PEPCK and CAR mRNA in the presence 
of 5mM glucose, whereas PB reduced their mRNA levels in glucose free condition. Here, 
we demonstrated that fasting and glucose depletion both can induce CAR and PEPCK, 
and this induction is attenuated upon PB treatment in mouse liver and in a hepatoma cell 
line. 
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Figure 1.1 CAR and PEPCK induced gene expression by fasting and glucose depletion. 
Total RNA was isolated from the livers of 16 hour fasted mice and injected with vehicle or PB 50 mg/kg. 
pepck (A) and car (B) mRNA were quantified by RT-PCR and standardized to GAPDH. Results represent 
means of five different mice ± S.D. with each determination done in triplicates (*, p<0.05). AT3F mouse 
hepatoma cells were cultured with or without glucose for 24h and treated with PB 500 µM for 16h. pepck 
(C) and car (D) mRNA were quantified by RT-PCR and standardized to GAPDH. 
 
Interestingly, glucose depletion from the medium induces AMPK activation in both 
cytosol and nucleus of mAT3F cells (Figure 1.2). This activation is correlated with the 
phosphorylation of  
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Figure 1.2 AMPK activation by PB in the absence of glucose. 
AT3F mouse hepatoma cells were cultured with or without glucose for 24h and treated with PB 500 µM for 
4h. Nuclear and cytosolic fractions were prepared according to the protocol described in material and 
methods. Expression of activated AMPKαt172, pACC and mouse CAR were shown by western blot. 
 
acetyl-coA carboxylase (ACC), an important enzyme in the regulation of fatty acid 
oxidation and lipogenesis and a target of AMPK in the liver. Furthermore, AMPK 
activation only occurs in the absence of glucose. More interestingly, in the absence of 
glucose, phenobarbital activates AMPK more efficiently in the nuclei than in the cytosol 
of AT3F cells. Altogether, these results show that AMPK is activated by glucose 
depletion and that PB may differently activates AMPK according to its location in the 
cell. Suprisingly, in this experiments, neither glucose depletion nor PB treatment changed 
CAR location in the cell, even though the western blot showed that, in the presence of 
glucose and upon PB treatment, CAR has the tendency to accumulate in the nucleus 
(Figure 1.2 lower pannel). 
 
CAR dependent effect induced by glucose depletion 
It is well established that the induction of cyp2b10 during fasting is CAR dependent 
[109]. Here in, for the first time, we demonstrate that like CAR and PEPCK mRNA, 
cyp2b10 is induced by the absence of glucose in the culture medium in AT3F cells 
(Figure 1.3A). Unfortunately, no induction of cyp2b10 has been seen upon PB. 
Moreover, our experiments show that, upon glucose depletion, the cyp2b10 induction is 
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blunted by treatment with phenobarbital. It is likely, that glucose interferes with the PB 
induction in this mouse hepatoma cell line.  
 
Figure 1.3 cyp2b10 induction in the absence of glucose. 
AT3F mouse hepatoma cells were cultured with or without glucose for 24h and treated with PB 500 µM for 
16h. cyp2b10 (A),  pxr (B) and cyp3a11 (C) mRNA were quantified by RT-PCR and standardized to 
GAPDH. 
 
The nuclear receptor pxr (Figure 1.3B) and its target gene cyp3a11 (Figure 1.3C) are both 
induced upon PB treatment, whereas no induction has been seen upon glucose depletion. 
Taken together, these results suggest that CAR is the only xenosensor whose expression 
as well as its target gene expression is regulated by glucose levels in the cell.  
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Effect of insulin on CAR mRNA expression 
Since fasting and glucose depletion induced CAR expression, the effect of insulin was 
also tested. As previously mentioned (introduction), dexamethasone and cAMP mimics 
the fasting effects in the cell. Dexamethasone mimics corticoids effects and cAMP 
mimics the glucagon induced effect. The combinatorial effect of dexamethasone and 
cAMP induced PEPCK gene transcription (Figure 1.4A), PGC-1α (Figure 1.4B) and 
CAR (Figure 1.4C) expression in primary human hepatocytes in culture. It is well 
established that, in the post-prandial state insulin inhibits endogenous glucose production 
by repressing the expression of numerous gluconeogenic genes including PEPCK and 
PGC-1α. Here, we show that the effect of insulin is extended to CAR mRNA levels. 
Insulin represses CAR mRNA which suggests that CAR is an insulin responsive gene and 
it may be involved in the molecular mechanism that regulates the fasting-feeding 
transition. The possible role of CAR in glucose homeostasis will be discussed below 
(discussion). 
CAR is involved in the regulation of PEPCK  
 
Regulation of endogenous PEPCK 
In order to test whether CAR can regulates PEPCK gene transcription, we transfected   
increasing amount of hemaglutinin-tagged human CAR into HepG2 cells (Figure 1.5A).  
This hepatoma cell line has been chosen because its glucose insensitivy. The activation of 
gluconeogenic genes and especially PEPCK has never been reported in this cell line. 
Thus, we then assessed PEPCK, by measuring mRNA levels via reversed-transcription 
experiments. PEPCK mRNA dose-dependently increased upon CAR transfection (Figure 
1.5B). Furthermore, the PEPCK induction seems to be potentiated by dexamethasone and 
cAMP upon transfection of 5 µg of CAR cDNA. This result is another demonstration of 
CAR potency in dex/cAMP induction of PEPCK gene transcription. Interestingly, in 
HepG2 cells increased transfected amount of CAR repressed PGC-1α expression even in 
the presence of dexamethasone and cAMP (Figure 1.5C). Since PEPCK gene 
transcription is induced upon human CAR transfection without any correlation with PGC-
1α expression, we can argue that PGC-1α mRNA induction is not necessary for the CAR-
mediated induction of PEPCK promoter activity. 
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Figure 1.4 CAR, PEPCK and PGC-1α expression in primary human hepatocytes in culture. 
Primary human hepatocytes were cultured with 5 mM or without glucose for 24h and treated with PB 500 
µM for 16h. PEPCK (A), PGC-1α (B) and CAR (C) mRNA were quantified by RT-PCR and standardized 
to 18S. Results represent means of three different donors ± S.D. with each determination done in triplicates 
(*, p<0.05). 
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Figure 1.5 CAR, PEPCK and PGC-1α expression in HepG2 cells. 
Human hepatoma cell line (HepG2) were cultured in DMEM 5 mM glucose and transfected with psG5 
empty vector or 0.1, 1, 5 and 10 µg of psG5-hCAR.  The cells were then treated with dexamethasone 10 
µM and dibutyryl-cAMP 100 µM for 24h. CAR (A), PEPCK (B) and PGC-1α (C) mRNA were quantified 
by RT-PCR and standardized to 18S.  Each determination was done in triplicates (*, p<0.05). 
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Positive effect of CAR on PEPCK transcriptional regulation is mediated 
by the -467/+67 enhanceosome 
Since we showed that CAR induces endogenous PEPCK in HepG2 cells, it was logical to 
locate the targeted region of the PEPCK promoter. We then co-transfected human CAR 
and the -467/+67 fragment of the rat PEPCK promoter (PEPCK-LUC) in CV-1 cells. 
This fragment of the PEPCK promoter was shown to mediate most of the hormonal 
response that trigger gluconeogenesis during fasting. CAR dose-dependently increased 
PEPCK activity in HepG2 cells (Figure 1.6). This induction was even more potent upon 
dexamethasone/cAMP treatment. More importantly, the repressive effect of 
phenobarbital on induced-PEPCK promoter activity reached its maximum when the 
highest amount of CAR is transfected (Figure 1.6A). This finding confirms the role of 
CAR as mediator of the PB effect on PEPCK promoter activity. Interestingly, the 
combination of CAR transfection, phenobarbital and dex/cAMP treatment leads to the 
strongest repression of PEPCK activity. 
In order to show that the activation of CAR by a ligand may also affect PEPCK promoter, 
we repeated the previous experiment in cells treated with a ligand of human CAR, 50 nM 
of 6-(4-chlorophenyl) imidazo [2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-
dichlorobenzyl)oxime (CITCO). Suprisingly, CITCO did not repress PEPCK promoter 
activity, even in the presence of CAR (Figure 1.6B). Moreover, CITCO potentiates the 
inductive role of CAR on induced PEPCK promoter activity. 
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Figure 1.6 CAR transactivates PEPCK promoter. 
CV-1 cells were co- transfected with psG5hCAR and -465+67 PEPCK-LUC promter.  The cells were then 
treated with dexamathasone 10 µM (Dex), dibutyrylcAMP 100 µM (Dbtr) and PB 500 µM (A) or CITCO 
50 nM (B) for 24h. The cells were lysed and luciferase activity was determined as described under material 
and methods. Each determination was done in fourplicates (*, p<0.05). 
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Protein Kinase A (PKA), a potential upstream regulator of CAR 
Protein Kinase A (PKA) is the key enzyme that links the cytosolic increased cAMP 
concentration enhanced by glucagon, and the transcriptional activity mediated by CREB 
(cf introduction). To test whether this enzyme could be the upstream regulator of CAR-
mediated induction of PEPCK, we co-transfected CAR and the catalytic subunit of PKA 
with PEPCK-LUC in CV-1 cells (Figure 1.7A). Here we show an additive effect of CAR 
and PKA on PEPCK promoter activity. However, no significant differences are noted 
between vehicle, CITCO or dexamethasone/cAMP treatment. 
The treatment of the cells by meclizine, a described antagonist of human CAR, 
completely reversed the effect of cAMP and dexamethasone on PEPCK (Figure 1.7B). 
Interestingly, this effect was shown only when both CAR and PKA are co-transfected. 
Altogether these findings strengthen the role of CAR as an important mediator in fasting 
response, especially in the regulation of PEPCK.  
This cooperation between CAR and PKA was intriguing; we thereby decided to test the 
effect of this co-transfection on CAR target DNA elements. We co-transfected CAR and 
the catalytic subunit of PKA with NR1-LUC, a 51 base pairs element found in the 
promoter of CAR target genes. Here we show that the cotransfection of CAR and PKA 
dose dependently activates NR1-LUC, suggesting that both CAR and PKA cooperates in 
the regulation of CAR target genes (Figure 1.7C). These findings reveal a potential cross-
talk between drug metabolism and endogenous glucose production regulation. 
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Figure 1.7 PKA and CAR additive effects. 
CV-1 cells were co- transfected with psG5hCAR, active catalytic subunit of PKA (PKAc) and -465+67 
PEPCK-LUC promter.  The cells were then treated with dexamathasone 10 µM (Dex), dibutyrylcAMP 100 
µM (Dbtr) and CITCO 50 nM (A) or meclizine 1 µM for 24h. The cells were lysed and luciferase activity 
was determined as described under material and methods.  
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Role of fasting and diet. 
Metabolic parameters: Glyceamia and body weight 
Most of the previous data presented in this thesis were achieved in human or mouse 
hepatoma cell line. However, the physiological relevance of CAR function in glucose 
homeostasis remains unclear. In order to understand, how CAR regulates PEPCK in vivo, 
wild type (wt) and CAR KO mice were fed, fasted and refed on a high carbohydrate diet 
(HC) according to the protocol showed in Figure 2.1 and described under material and 
methods. 
 
Figure 2.1 High carbohydrate diet protocol. 
 
Mice were refed upon HC diet following fasting to boost endogenous glucose production. 
In our experiment, all the CARKO mice were slightly lighter than the wild type mice 
(Figure 2.2A). Interestingly, the refed animals are slightly heavier than the fasted ones, 
even though 16 hours of HC diet may not be enough to note a significant increase in total 
body weight. Nonetheless, the liver weight of refed animals is significantly higher than 
the fasted animals (Figure 2.2B), which suggest that 16h upon this diet compensates the 
fasting liver weight loss. These animals may have stored the excess of carbohydrates into 
glycogen and latter on into fat. Unfortunately, no accumulation of lipid droplet has been 
seen in those livers. 
We also measured glycaemia in these animals. Surprisingly, in fed state, CAR KO had a 
lower glycaemia than wild type animals (Figure 2.2C). However, during fasting, 
glycaemia in both wt and CARKO decreased to 4 mM and, when refed on HC, glycaemia 
reaches back the same levels as in the fed state. These findings suggest that CAR is 
involved in the regulation of glycaemia during the fasting-feeding transition. 
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Figure 2.1 CAR regulates glycaemia during fasting/feeding transition. 
Wild-type mice (□, open bars) and CAR KO mice (■, black bars) were fasted and refed according to the 
protocol previously described. Total body weight (A) and liver weight (B) were assessed the day of the 
sacrifice. Blood glucose (C) was measured at each nutritional transition. Results represent means of four 
different mice ± S.D. All values obtained are compared to the wild type fed animals. (**, p<0.01) 
 
Glucose homeostasis and lipogenesis regulation by CAR. 
To understand the role of CAR in the regulation of glycaemia, we performed quantitative 
PCR (qPCR) to assess the expression of several genes encoding for proteins involved in 
glucose homeostasis from the liver of wt and CARKO animals. Our data show that in 
both genotypes, pepck, pgc-1α and hnf-4α were nicely inducible upon fasting (Figure 
2.2A upper pannel). No significant differences were noted between wt and CARKO 
mice, which suggest that the enhancement of gluconeogenesis is not affected in CARKO 
animals. However, in the fasted state, the expression of genes encoding for proteins 
involved in glucose transport (glut2) and phosphorylation (gk) in the liver is significantly 
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lower in CARKO livers (Figure 2.2A, lower pannel). Taken together, these data suggest a 
role of CAR in the regulation of glucose transport and phosphorylation in the hepatocyte. 
It is well established that the deacetylase sir2 modulates ageing in several species and 
controls the gluconeogenic/glycolytic pathways in liver in response to fasting. Here in, 
we found that sir2 was also downregulated in CARKO samples (Figure 2.2A, lower 
pannel). 
As previously mentioned (results part I), fasting induces the expression of CAR and its 
target gene cyp2b10 in the liver (Figure 2.2B). Moreover, in CARKO livers, no induction 
of cyp2b10 was observed neither in refed nor in fasted state. This finding strongly 
supports the CAR dependency in cyp2b10 induction. 
It is well established, that chronic feeding upon high carbohydrate diet can induce 
lipogenesis in the liver, because the excess of carbohydrate will ultimately be stored as 
fat. We then measured the genes encoding for proteins involved in lipogenesis in wt and 
CARKO livers. Surprisingly, in the fed state, the expression of srebp-1c is higher in 
CARKO livers (Figure 2.2C upper panel). However, in the fed state, the expression of all 
the other genes involved in lipogenesis (s14, acc1, acc2 and fas) is significantly lower in 
CARKO livers (Figure 2.2C lower panel). More importantly, during fasting, the 
expression of acc1, acc2, fas and s14 is higher in CARKO livers as compared to the wt 
livers. All these findings point out a new role of CAR in the regulation of nutritional 
transition. This role of CAR will be discussed below. 
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Figure 2.2 CAR regulations of glucose homeostasis and lipogenesis. 
Wild-type mice (□, open bars) and CAR KO mice (■, black bars) were fasted and refed according to the 
protocol previously described. Total RNA was isolated from the livers and mRNA product from genes 
encoding for proteins involved in glucose homesotasis (A), drug metabolism (B) and lipogenesis (C) were 
quantified by RT-PCR and standardized to GAPDH. Results represent means of four different mice ± S.D. 
with each determination done in triplicates (*, p<0.05:**,p<0.01).  
 
 
High carbohydrate diet 
 
We previously showed that CAR regulates the expression of genes involved in glucose 
homeostasis and in lipogenesis. To understand how CAR regulates glucose homeostasis, 
we fed wild type and CARKO mice with a high carbohydrate diet / Low fat (HC diet) for 
12 weeks (cf material and methods). 
We measured glycaemia over 80 days, and surprisingly, HC diet did not significantly 
increase glycaemia in both groups. Blood glucose has been taken every morning at 8:00 
am, unfortunately, in both groups, a lot of variations occurred from one mouse to another 
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(Figure 2.3A). More importantly, After 80 days under HC diet, CARKO mice exhibit a 
significant higher glycaemia than the wild type mice, which suggest than CAR may 
controls blood glucose concentration under chronic HC diet. Another surprising 
observation is the relative constancy of CARKO mice glycaemia over time as compared 
to the normal animals (Figure 2.3B) 
 
 
Figure 2.3 Glycaemia. 
Wild-type mice (□, open bars) and CAR KO mice (■, black bars) were fed with a normal lab chow or with 
high carbohydrate diet (HC) according to the protocol described under mat et methods. Glycaemia was 
assessed over 80 days in both groups and under both diets (A) and (B). Blood glucose concentration 
measured the day of the sacrifice (D80) (C). Results represent means of five different mice ± S.D. All 
values obtained are compared to the wild type fed animals. (*, p<0.05). 
 
 
As expected, during the study, total body weight increased over time in normal and 
CARKO mice (Figure 2.4 A,B). Moreover, normal animals fed under HC gained more 
weight than those fed under normal diet. (Figure 2.4D). Interestingly, only when fed 
under a normal diet, after 80 days, CARKO mice became heavier than the normal mice 
(Figure 2.4C). However, during the whole study, and independently of the diet, CARKO 
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animals gained more weight than the wild type ones, even though, this difference is 
bigger in the normal diet fed group (Figure 2.4D). 
 
 
 
 
Figure 2.4 Total body weight. 
Wild-type mice (□, open bars) and CAR KO mice (■, black bars) were fed with a normal lab chow or with 
high carbohydrate diet (HC) according to the protocol described under mat et methods. Total body weight 
was assessed over 80 days in both groups and under both diets (A) and (B). Total body weight measured 
the day of the sacrifice (D80) (C). Results represent means of five different mice ± S.D. All values obtained 
are compared to the wild type fed animals. (*, p<0.05). 
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We then performed qPCR to assess, in the liver, the expression of genes encoding for 
proteins involved in glucose and lipid metabolism. After, 12 weeks under a normal chow 
diet, glut2 mRNA level is higher in CARKO as compared to wild type animals (figure 
2.5A). Surprisingly, glut2 and carbohydrate response element binding protein (chrebp) 
(figure 2.5C) expression were not induced by HC diet, whereas glucokinase (gk) (figure 
2.5B) expression tended to increase. These observations are may be due to a negative 
regulatory mechanism enhanced by a chronic ingestion of carbohydrate and can also 
explain why 12 weeks of HC diet did not increase glycaemia in these animals. 
 
 
Figure 2.5 High carbohydrate diet and glucose homeostasis. 
Wild-type mice (□, open bars) and CAR KO mice (■, blue bars) were fed with a normal lab chow or with 
high carbohydrate diet (HC) according to the protocol described under mat et methods. Total RNA was 
isolated from the livers and mRNA product from genes encoding glut2 (A), glucokinase (gk) (B) and 
carbohydrate response element binding protein (chrebp) (C) were quantified by RT-PCR and standardized 
to GAPDH. Results represent means of 6 different mice ± S.D. with each determination done in triplicates 
(*, p<0.05:**,p<0.01).  
 
Interestingly, the expression of genes encoding for proteins involved in lipid metabolism 
such as fatty acid synthase (fas) (Figure 2.6A), s14 (Figure 2.6B) and acetyl-coA 
carboxylase-1 (acc1) (Figure 2.6D) are all induced upon HC diet in CARKO livers. 
Except for s14 expression, under normal diet, no differences in the expression of fas, cpt-
1, acc1, acc2 and srebp1-c have been noted between wild type and CARKO livers. The 
mRNA levels of carnitine palmitoyl transferase (cpt-1) (Figure 2.6C) and acc2 (Figure 
2.6F), two proteins involved in fatty acid beta oxidation, are induced under HC diet in 
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livers of normal mice. However, the mRNA level of cpt-1 is lower in CARKO livers, fed 
with HC diet. Finally, srebp-1c, an essential gene for lipogenesis was shown to be 
induced by insulin and by high fat diet. Unexpectedly, in our study, and as for most of the 
genes that we have measured, srebp-1c mRNA expression was not induced by HC diet 
(Figure 2.6E). 
 
 
Figure 2.6 High carbohydrate diet and lipid homeostasis. 
Wild-type mice (□, open bars) and CAR KO mice (■, blue bars) were fed with a normal lab chow or with 
high carbohydrate diet (HC) according to the protocol described under mat et methods. Total RNA was 
isolated from the livers and mRNA product from genes encoding fatty acid synthase (A), s14 (B), carnitine-
palmitoyle-transferase (cpt-1) (C), acetycoA carboxylase (acc1) (D), srebp-1c (E) and acc2 (F) were 
quantified by RT-PCR and standardized to GAPDH. Results represent means of 6 different mice ± S.D. 
with each determination done in triplicates (*, p<0.05:**,p<0.01).  
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Interplay between CAR and AMPK 
 
CAR was well established as a xenosensor in mediating the effect of PB in drug 
metabolism. However, as we previously mentioned, CAR was also described as a 
regulator of glucose homeostasis in mouse. Interestingly, we showed that PB increases 
the activity of AMP-activated kinase (AMPK). Indeed, this kinase is necessary to mediate 
the induction of CYPs by PB in human and in mouse livers [63, 64]. As AMPK was also 
found to regulate gluconeogenesis, and in order to point out a relationship between 
AMPK and CAR, we tested the regulation of AMPK activation in primary hepatocytes in 
culture from CARKO animals. The hepatocytes were cultured in glucose free or in 25 
mM glucose containing medium for 24H and were infected with an adenovirus encoding 
for β-galactosidase (βgal) or for hematoglutinin-tagged human CAR (HAhCAR). We 
treated the cells with 500 µM phenobarbital or 1 mM metformin (Met) (Figure 3.1) and 
assessed AMPK activation by western blot. 
 
 
 
Figure 3.1 AMPK activation in CARKO hepatocytes. 
Primary hepatocytes in culture from CARKO animals were cultured in glucose free or in a 25 mM glucose 
containing medium for 24H. The hepatocytes were infected with adenovirus encoding for HAhCAR or for 
an adenovirus encoding the β-galactosidase protein (βgal). The cells were treated for 4H with 500 uM of 
phenobarbital (PB) or metformin 1 mM (Met). The expression of phosphorylated AMPK Thr172 
(ampkT172), acetyl-coA carboxylase (ACC) and the phosphorylated form of acc (pACC) were assessed by 
western blot.  
 
 
         
 54 
In the absence of glucose, metformin is a better activator of AMPK than phenobarbital.  
However, upon 25 mM glucose, both drugs lose their efficacy in inducing AMPK. This 
effect seems to be even more pronounced in the presence of exogenous human CAR 
(Figure 3.1 right pannel). In this study, the activation of AMPK by phenobarbital and 
metformin leads to the phosphorylation of one of the AMPK target, the acetyl-coA 
carboxylase (pacc). Interestingly, the PB activation of AMPK is blunted in the presence 
of human CAR. This effect of PB on AMPK activation can be correlated with the 
phoshporylation of acc. Altogether, this data suggest that the PB-mediated activation of 
AMPK is glucose and CAR dependent.  
To avoid the utilization of viruses and to strictly compare the activation of AMPK in 
CARKO and normal animals, we repeated the previous experiment without metformin 
treatment in hepatocytes from CARKO animals. Surprisingly, in this experiment PB did 
not have any effect nor on AMPK neither on pACC (Figure 3.2). However, it was 
intriguing to see that the expression of the AMPK α1 subunit was clearly higher in 
CARKO hepatocytes, whereas the expression of ACC and pACC were lower. In CARKO 
hepatocytes, the higher expression of AMPK α1 subunit did not correlate with a stronger 
phosphorylation of ACC. 
 
 
Figure 3.2 AMPK expressions in CARKO hepatocytes. 
Primary hepatocytes in culture from CARKO animals were cultured in glucose free or in a 25 mM glucose 
containing medium for 24H. The hepatocytes were treated for 4H with 500 uM of phenobarbital (PB). The 
expression of phosphorylated AMPK Thr172 (ampkT172), AMPK α1 subunit (AMPK α1), acetyl-coA 
carboxylase (ACC) and the phosphorylated form of acc (pACC) were assessed by western blot.  
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This result suggests that CAR may regulate the expression of AMPK α1 subunit, thereby 
regulating its activity. Moreover, this experiment show for the first time a CAR 
dependent and AMPK independent regulation of the phosphorylation of acetyl-coA 
carboxylase (pACC). 
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Abstract: 
 
Phenobarbital (PB) lowers glyceamia in patients with diabetes by repressing genes that 
encode enzymes involved in gluconeogenesis such as phosphoenolpyruvate 
carboxykinase (PEPCK). Recently, phenobarbital was shown to activate the energy 
sensor AMP-activated kinase (AMPK) protein. In this study, we first show that PB dose-
dependently decreases PEPCK in primary human hepatocytes. Activation of AMPK by 
phenobarbital and 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside (AICAR), 
inhibited PEPCK expression whereas an inhibitor of AMPK, compound C, reversed this 
inhibition in mouse and human hepatocytes in primary culture. Phenobarbital has no 
effect on PEPCK expression in the liver of mice deleted of AMPK alpha1 and alpha2 
catalytic subunits. In mouse liver, activation of AMPK is necessary but not sufficient to 
trigger the effect of phenobarbital on PEPCK mRNA. Constitutive androstane receptor 
(CAR), a nuclear receptor activated by PB and was shown to down-regulate PEPCK 
expression. In coactivator assays, phenobarbital and AICAR repress the interaction 
between CAR and the peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-
1α), a known regulator of PEPCK.  
On the basis of these findings, we propose a new mechanism by which phenobarbital 
represses PEPCK. The activation of AMPK by phenobarbital simultaneously potentiates 
nuclear accumulation of CAR and increases AMPK-CAR interaction. Once activated, the 
AMPK-CAR complex prevents PGC-1α from its recruitment to the PEPCK promoter. 
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Introduction 
 
Phenobarbital (PB) is an anticonvulsant and hypnotic drug and the prototype of chemicals 
which induce pleiotropic effects in the liver, including liver hypertrophy, tumor 
promotion and the regulation of genes coding for enzymes such as cytochrome P450s 
(CYPs) or transporters that regulate drug disposition. Drug metabolism is mainly 
controlled by transcriptional activation of hepatic genes encoding drug metabolizing 
enzymes and transporters. 
The induction of human cytochrome P450 CYP2B6 and its mouse ortholog Cyp2b10 by 
PB is mediated by the nuclear receptor constitutive androstane receptor (CAR, NR1I3) 
which binds to its cognate sequence named phenobarbital response enhancer module 
(PBREM) [187].  In untreated primary mouse hepatocytes, CAR is retained in the 
cytoplasm within a protein complex of chaperones and co-chaperones such as heat shock 
protein 90 (HSP90) [188], and a protein called cytoplasmic CAR retaining protein 
(CCRP)[189]. Exposure to xenobiotics such as PB causes CAR to dissociate from this 
complex and to transfer into the nucleus where it forms a heterodimer with retinoid X 
receptor and binds to its consensus DNA sequences of target genes [190]. However, this 
mechanism is incompletely understood and cannot explain all PB effects on gene 
transcription. Earlier studies have shown that PB lowers glycaemia of patient with 
diabetes as well as in animal models of diabetes such as streptozotocin injected rats [191, 
192]. Furthermore, it has been reported that gluconeogenesis was inhibited in liver of 
mice fed on a normal chow diet and treated with PB [110]. Active gluconeogenesis and 
increased hepatic glucose production is the main cause of post-prandial hyperglycemia 
observed in Non-Insulin Dependant Diabetic (NIDDM) patients. 
The gluconeogenic pathway converts non carbohydrate precursors into glucose and helps 
sustain a normal blood glucose concentration under fasting conditions. PEPCK catalyses 
the first irreversible step in this process, the conversion of oxaloacetate to 
phosphoenolpyruvate. The PEPCK gene is tightly regulated by glucagon, glucocorticoids, 
retinoic acid, thyroid hormone, and insulin [134, 193], as well as glucose [194]. Each of 
the hormones exerts its effect through a hormone response unit located within the 
proximal 500 bp of the PEPCK promoter and consisting of DNA elements and associated 
transcription factors [195]. Each of these DNA elements was also shown to bind multiple 
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transcription factors, such as retinoic acid receptor (RAR)[196], fork-head box (FOX) 
family members [197], CCAATT/enhancer binding protein (C/EBP α), cAMP response 
element binding protein (CREB) [198] and hepatic nuclear transcription factor 4α 
(HNF4α) [199]. These DNA-binding transcription factors function by recruiting 
coregulators to the promoter, which in turn results in the activation or repression of 
transcription. However, it is not clear whether any or all of these proteins serve obligatory 
roles, which combinations are sufficient for regulation, or if some act to amplify or 
suppress an existing lower level response.  
Recently, it has been shown that CAR is another player in the regulation of PEPCK 
transcription. In mouse liver, CAR binds to the PEPCK promoter upon PB treatment 
[200]. Moreover, CAR may compete with HNF-4α for its DNA binding site and for its 
interaction with coactivators. Many coactivators were described to be recruited to the 
promoter of PEPCK by ligand-activated transcription factors to form a functional 
complex with other components of the transcription machinery. For example, the 
peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1α) is a critical 
regulator of gluconeogenesis in response to fasting [201]. PGC-1α induces basal and 
hormone-induced PEPCK gene transcription by promoting a complex formation between 
HNF4 α and glucocorticoid receptor (GR). More importantly, CAR was shown to interact 
with PGC-1α, but no functionnal assay has been previously described regarding this 
interaction. 
Gluconeogenesis is a energy-demanding process, consuming 4 ATP molecules per 
molecule of glucose produced. When gluconeogenesis is sustained it results in ATP 
depletion in the cell. It is now well established that AMP-activated protein kinase 
(AMPK) is a master switch of energy demand by inhibiting anabolic pathways and 
stimulating catabolic pathways to control ATP levels [167]. AMPK is a heterotrimeric 
complex ubiquitously expressed consisting of a catalytic subunit α, and two regulatory 
subunits, β and γ [202]. All three subunits have been characterized, and each subunit is 
encoded by two (α1α2, β1β2) or three genes (γ1, γ2, γ3). Formation of the trimeric 
complex is necessary for optimal kinase activity [203]. Changes in the cellular energy 
state activate AMPK through mechanisms involving an AMP allosteric regulation and 
phosphorylation by an upstream kinase of threonine residue 172 within the activation 
loop of the alpha subunit [204]. Suppression of expression of gluconeogenic genes such 
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as PEPCK and glucose-6-phosphatase (G-6-Pase) was observed in rat hepatoma cells 
(H4IIE) in response to the non specific AMPK activator, 5-aminoimidazole-4-
carboxamide riboside (AICAR) [205] and in mice after adiponectin administration [179] 
or in obese diabetic db/db mice after adenovirus-mediated delivery of a constitutively 
active AMPK [206, 207].  
The inhibitory effect of PB on gluconeogenesis is not observed in transgenic mice in 
which the CAR gene is deleted [14]. Furthermore, we reported that PB activates AMPK 
and this activation is necessary for the transcription of cytochrome P450s in human and 
mouse liver [64]. Based on these observations we have designed experiments to test 
whether inhibition of PEPCK expression by PB is mediated in an AMPK/CAR dependent 
manner. We have established that this effect occurs in human hepatocytes in primary 
culture and that AMPK and CAR are necessary to trigger the effect of PB on PEPCK 
expression in mouse liver. Moreover, we demonstrate a functional interaction and 
cooperation between CAR and PGC-1α to transactivate the PEPCK promoter. Finally, 
our results suggest that in primary human hepatocytes, AMPK binds to CAR to prevent 
PGC-1α from its recruitment to PEPCK promoter, thereby inhibiting PEPCK 
transactivation. 
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Results 
 
PB and AICAR repress PEPCK in mouse and human hepatocytes in primary 
culture 
 
In primary culture of human hepatocytes we observed a dose dependent inhibition of 
PEPCK expression by phenobarbital (Fig. 1A). In order to be able to detect PEPCK 
mRNA in cell culture, cells were kept in serum free and glucose free medium. The 
induction of CYP2B6 by PB further validated our culture system of human hepatocytes 
for this study (Fig.1B). Intraperitoneal injection of 50 mg/Kg of PB in mice fasted for 16 
hours also led to an inhibition of PEPCK expression in the liver at 10 hours of exposure 
to the drug (datas not shown). This confirms both in vivo and in vitro the inhibitory effect 
of PB on the PEPCK gene.  
AICAR is a cell permeable compound phosphorylated to the monophosphate form Z-
Mono- Phosphate (ZMP) which can accumulate in the cell, mimicking the effect of AMP 
on the AMPK phosphorylation and activation [208]. In cells exposed to dexamethasone 
(1µM) and cAMP (10µM) in order to induce PEPCK, the  pharmacological activation of 
AMPK with AICAR dose-dependently inhibited PEPCK expression in primary culture of 
human and  mouse hepatocytes (Fig 1C, 1D) This inhibitory effect was antagonized by 
pre-incubation of cells with Compound C, an inhibitor of AMPK. Inhibition of PEPCK 
expression by AICAR and the antagonistic effect of compound C suggest an AMPK 
dependent repression of the PEPCK gene by PB in vitro.  
 
AMPK is necessary for the inhibitory effect of phenobarbital on PEPCK mRNA in 
mice 
 
To test the role of AMPK in the inhibition of PEPCK by PB, we injected  PB 
(100mg/Kg) in wild type (wt) and mice where the α1 and α2 AMPK subunits were 
specifically deleted in the liver (AMPK α1/α2LS KO mice) (Fig. 2A). PB represses 
PEPCK in the liver of wild type mice, whereas no inhibition was observed in α1/α2LS 
KO mice confirming the important role of AMPK in the repression of PEPCK by PB 
(Fig.2A). To rule out possible effects of metabolic changes as a consequence of the 
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AMPKα1 and α2 deletion in the liver, we performed primary culture of hepatocytes from 
wt and α1/α2LS KO mice (Fig. 2B). The inhibition of PEPCK was only observed in 
hepatocytes from wt animals after 12 hours exposure to 500µM PB (Fig. 2B) tending to a 
strong support for the role of AMPK in the regulation of the basal transcription of the 
PEPCK gene. It is important to note that PEPCK expression was much higher in 
hepatocytes from α1/α2LS KO mice as compared to hepatocytes from wt mice. Moreover, 
PB was unable to repress PEPCK gene expression in hepatocytes from α1/α2LS KO mice. 
The AMPK inhibitor Compound C (CompC) was able to reverse the inhibitory effect of 
PB on PEPCK expression only in hepatocytes from wt mice but not in hepatocytes from 
α1/α2LS mice. Taken together these results confirm the necessary role of AMPK in the 
effect of PB on PEPCK in human and mouse hepatocytes in primary culture. 
The role of AMPK in PEPCK regulation was further tested in human hepatocytes in 
primary culture infected with an adenovirus expressing a constitutively active, truncated 
form of AMPK α2 subunit (ad-AMPK-CA-α2, Fig. 2C). The ad-AMPK-CA-α2 was able 
to partially repress PEPCK expression even in the presence of dexamethasone (1µM) and 
cAMP (10µM) (Fig.2C). 
Interestingly, the inhibition of PEPCK by PB and AICAR were much stronger in cells 
infected with ad-AMPK-CAα2 than in cells infected with an adenovirus expressing β-
galactosidase (AdβGal).  
These results again support the necessary role of AMPK in the inhibition of PEPCK 
expression by PB in mouse and human hepatocytes in primary culture.  
 
CAR mediates the PB effect on gluconeogenesis in mouse primary hepatocytes. 
 
Previous studies described a CAR dependency of the PB effect on gluconeogenesis [110]. 
To test this hypothesis, we cultured primary mouse hepatocytes from wild type (wt) and 
CAR -/- animals under conditions where PEPCK and G6Pase are induced before 
exposure to PB (500 uM) (Fig. 3A). Unexpectedly, in absence of dexamethasone and 
cAMP, PB was able to significantly induce PEPCK expression in hepatocytes from CAR 
-/- mice (Fig. 3A). The same tendency is observed for G6Pase mRNA (Fig. 3B). The 
inhibition of PEPCK and G6Pase expression by PB was observed only after 8 hours of 
         
 63 
culture in hepatocytes from wt mice. The efficiency of dexamethasone and cAMP to 
induce PEPCK and G6Pase expression and insulin to repress PEPCK is similar in 
hepatocytes from wt and CAR -/- mice. Addition of Compound C (CompC) reversed the 
inhibitory effect of PB on both enzymes only in hepatocytes from CAR -/- mice 
confirming the involvement of AMPK in the repression of gluconeogenesis by PB. 
Suprisingly, in hepatocytes from wild type animals compC failed to reverse the inhibitory 
effect of PB on G6Pase expression (Fig. 4B). The lack of an effect of PB on 
gluconeogenic genes in CAR -/- hepatocytes cannot be attributed to a difference in 
AMPK expression since both AMPK alpha 1 and alpha 2 subunits were equally 
expressed  in wild type and in CAR -/- mice livers (Fig.3C).  
To test whether this regulation of PEPCK by PB reflects inhibition of glucose production, 
we measured glucose produced in culture medium in hepatocytes from wild type and 
CAR -/- mice (Fig. 3D). Glucose production is significantly decreased upon PB treatment 
in wt hepatocytes, whereas no significant changes have been observed in CAR -/- cells. 
Moreover, AICAR and metformin, both activators of AMPK, decreased by almost 60% 
glucose production in wt hepatocytes but their effect is attenuated in CAR -/-cells. This 
result shows that CAR is necessary to mediate the PB repressive effect on glucose 
production in hepatocytes. Furthermore, the attenuated effect of metformin and AICAR 
on glucose production in CAR -/- suggest that CAR may also play a role in mediating the 
effect of AMPK on gluconeogenesis. 
 
Interaction of PGC-1α, CAR and AMPK 
 
A large number of hormones and transcription factors have been shown to regulate the 
expression of PEPCK. Among them, FOXO1 has been proposed to be the mediator of the 
effect of PB on PEPCK (Kodama et al., 2003). We co-expressed hCAR and hFOXO1 in 
CV-1 cells and tested the transactivation of the -467/+69 fragment of the PEPCK 
promoter. We observed that hFOXO1 significantly increased PEPCK promoter 
transactivation, whereas hCAR had no effect. Surprisingly, we were unable to reproduce 
the co repressive effect of CAR and FOXO1 for the transactivation of the -467/+69 
fragment of PEPCK (Fig. 4A). The possible reasons for this discrepancy will be 
discussed below. Because the interaction between CAR and PGC1a has previously been 
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described (Shiraki et al., 2003) and because PGC-1α is a master regulator involved in the 
amplification of PEPCK induction by fasting (Lin et al., 2005), we decided to investigate 
the role played by PGC-1α on PEPCK promoter regulation by CAR. No functional assay 
has previously been performed on the CAR- PGC-1α interaction. The direct binding of 
PGC-1α to CAR was first tested by a co-factor assay as previously described (Shiraki et 
al., 2003). Briefly, the human CAR ligand binding domain (CAR LBD) fused to the Gal4 
DNA binding domain was used as bait and cotransfected with hPGC-1α and GAL4 
response element (Gal4RE) fused to luciferase. Luciferase activity reflects binding of 
CAR LBD to Gal4RE. Without any exogenous coactivator hCAR LBD shows a 
constitutive activity (Fig. 4B gray bar). hPGC-1α co-transfection clearly increases the 
binding of CAR LBD Gal4 to Gal4RE demonstrating an increase in hCAR LBD activity. 
As expected, addition of 500µM AICAR strongly disrupts this effect (Fig. 4B). Thus, we 
designed experiments to test the effects of  PGC-1α in combination with hCAR on the 
activity of the -467/+69 fragment of the PEPCK promoter in CV-1 cells (Fig 4B). The co-
activator hPGC-1α dose-dependently transactivated the PEPCK promoter in a hCAR 
dependent manner. More importantly, the potentializing effect of hPGC1a on PEPCK 
transactivation was blunted by addition of 500µM AICAR. Meanwhile the AICAR effect 
suggests a possible role of AMPK on hCAR and/or PGC1a activity.   
Altogether, these results indicate a functional binding of hPGC-1α to hCAR and suggest a 
role of this interaction on PEPCK transactivation. Furthermore, the effect of AICAR on 
this interaction suggests that AMPK may interact both with CAR and PGC-1α in the 
regulation of PEPCK. 
We now considered a possible direct interaction between AMPKα and CAR. Primary 
human hepatocytes were infected with Adenoviruses expressing hemagglutinin tagged 
hCAR (ad-HAhCAR) and myc tagged AMPKα2. Western blots of HAhCAR-
immunoprecipitated lysates show an increased interaction between CAR and AMPKα2 
protein upon PB treatment. In a second step, we performed the vice versa experiment by 
immunoprecipitating AMPK and assaying HA-hCAR by Western blot. This experiment 
shows the binding of AMPK to CAR enhanced by PB in human hepatocytes (Fig. 5A). In 
addition to coimmunoprecipitation experiment we analysed the CAR-AMPK interaction 
by a mammalian two-hybrid assay (Fig. 5B). The reporter activity was increased by 3 
fold when AMPKα2 is co-transfected with the human CAR ligand binding domain (CAR 
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LBD) fused to Gal4 DNA binding domain. This experiment shows that AMPK strongly 
enhances CAR activity. Furthermore, we used a recombinant HIS-AMPKα1 as a bait to 
bind hCAR on a Nickel affinity gel. Incubation of HIS-AMPKα1 with human 
hepatocytes protein lysates expressing Ad-HAhCAR revealed a binding between 
AMPKα1 and HAhCAR as shown by the co-elution profile detected by western blot (Fig. 
5C). HAhCAR protein is exclusively eluted in the presence of HIS-AMPKα1. Without 
AMPK, hCAR is washed out in the first fraction. Finally, in human hepatocytes 
expressing hCAR–EGFP, AMPKα2 subunit was detected in proximity of CAR 
suggesting a colocalisation of these two proteins in the nucleus upon PB treatment (Fig. 
5D).  
As we have previously mentioned, the cotransfection of CAR and PGC-1α increased 
PEPCK promoter activity in CV-1 cells. The cotransfection of AMPK leads to the 
repression of PEPCK (Fig. 5E). Interestingly, AMPK 1α dead kinase subunit inhibits the 
PEPCK transactivation, which suggests that the kinase acitiviy is not necessary to 
mediate the repressive effect of AMPK on PEPCK promoter activity. Altogether, these 
results strongly suggest that hCAR directly binds to human AMPKα subunit and that PB 
does enhance this interaction thereby leading to prevention of PGC-1α recruitment on 
PEPCK promoter. 
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Discussion  
 
The present study identifies a new molecular mechanism by which phenobarbital (PB) 
inhibits gluconeogenesis. We describe, for the first time a PB-enhanced interaction 
between human CAR and AMPK α2 subunit. This interaction leads to a synergistic action 
of CAR, PGC-1α and AMPK in the control of the regulation of gluconeogenesis. 
Furthermore, here in, we show that CAR and AMPK are both necessary to mediate the 
effect of PB on PEPCK expression. 
PEPCK is the rate limiting enzyme of gluconeogenesis process and is regulated by 
hormones involved in the fasting feeding transition. These hormones exert their effects 
through a hormone response unit located within the promoter (Chakravarty, et al. 2005). 
The deregulation of the transcriptional activity of PEPCK gene is associated with 
hyperglycaemia and insulin resistance observed in non insulin dependent diabetic patients 
(NIDDM). Moreover, earlier studies have shown that chronic PB treatment lowers 
glycaemia of patients with diabetes [191, 192]. Furthermore, others reported that hepatic 
gluconeogenic enzymes, such as PEPCK and G6Pase are repressed in PB-treated rats and 
mice [43, 44]. In this context, our study shows this inhibitory effect of PB in human 
hepatocytes in primary culture. 
However, the mechanism by which PB regulates gluconeogenesis remains unclear. It was 
found that CAR regulates the PB-induced repression of PEPCK [14]. CAR directly binds 
and represses FOXO1, a known positive regulator of PEPCK. Unfortunately our datas do 
not support this finding. This discrepancy of results may be attributed to the difference in 
the systems that have been used. It is not excluded that the molecular mechanisms that 
regulate PEPCK in mouse and in human are different which can also explain the 
discrepancy between the studies. Furthermore, Kodama et al., worked on an Insulin 
response sequence (IRS) which consist of 40 base pairs, whereas we used a 500 bp 
fragment of the PEPCK promoter. 
Here in, for the first time, we demonstrate a functional interaction and cooperation 
between CAR and PGC-1α to regulate the PEPCK promoter activity. Interestingly, the 
potentializing effect of PGC-1α on PEPCK transactivation was blunted by addition of 
AICAR, confirming the role of AMPK in such regulation. Meanwhile, there is no 
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evidence of phosphorylation of PGC-1α by AMPK or interaction between these two 
proteins despite a suggested link in muscle beta oxidation [209].  
We previously reported that PB activates AMPK in mouse and human livers and this 
activation is necessary for the PB-induced transcription of cytochrome P450s [63, 64]. 
Besides mediating the PB effect in CYPs regulation, AMPK also conveys the PB 
message on PEPCK since PB does not repress PEPCK in mice where α1 and α2 AMPK 
subunits were specifically deleted in the liver (AMPK α 1/ α 2LS KO mouse). Moreover, 
the AMPK inhibitor Compound C was able to reverse the inhibitory effect of PB on 
PEPCK expression only in hepatocytes from wt mice but not in hepatocytes from α 1/ α 
2LS mouse which confirm the role of AMPK in mediating the PB effect on PEPCK. As 
PB-independent pharmacological activation of AMPK leads to inhibition of 
gluconeogenesis, AMPK may be the key enzyme in the complex linked regulation of 
energy and drug metabolism. Nevertheless, the AMPK downstream targets in the 
regulation of CYPs and PEPCK have still to be identified. 
Hence we point out a new mechanism by which AMPK interact with CAR to repress 
PEPCK gene transcription. It was previously reported that AMPK, independently of its 
kinase activity, binds and co-activates the nuclear receptor peroxisome proliferator-
activated receptor α (PPAR α) in rat hepatocytes [210]. Herein, we demonstrated that 
AMPKα2 is co-localized with human CAR in primary human hepatocytes. Moreover, we 
showed that AMPKα1 directly binds to CAR and co-regulates its activity. This 
interaction may interfere with the complex interplay of proteins that regulate PEPCK, 
thereby leading to its inhibition.  
A recent study suggested that mouse CAR binds to PEPCK promoter upon PB treatment 
in mouse liver [200], thereby leading to competition between CAR and HNF4α for a DR1 
binding site and for co-activators recruitment. The authors showed that mouse CAR and 
HNF4α bind with the same affinity to PEPCK promoter. Therefore, in our system, low 
levels of endogenous HNF4α would be easily displaced by exogenous hCAR. However, 
PEPCK promoter activation requires important co-regulators such as PGC-1α. PB 
activates AMPK thereby leading to an interaction with CAR, which reduces the amount 
and/or the specificity of PGC-1α recruitment to induce PEPCK. One could assume that 
activation of AMPK by PB simultaneously potentiates nuclear accumulation of CAR and 
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increases AMPK-CAR interaction. Hence activated, the AMPK-CAR complex prevents 
PGC-1α from its recruitment to the PEPCK promoter.  
Our study indicate that AMPK and CAR are both necessary to mediate the PB inhibitory 
effect on PEPCK. This study describes for the first time an interaction between CAR and 
AMPK. Our experiments provide a new mechanism by which PB controls the energy 
sensor activation, thereby controlling the regulation of synthesis of de novo glucose 
molecules. It is clear that CAR is more than a xenobiotic sensor, but can also control the 
expression of gluconeogenic genes by interacting with AMPK. It would be of interest to 
test if CAR interferes with AMPK on the regulation of other target genes such as CYPs. 
We still do not know whether AMPK interaction with CAR involves phosphorylation or 
not. An increase binding of CAR to AMPKα1 upon PB treatment suggest the activation 
of AMPK as a step in this process. Meanwhile, we are currently investigating the CAR 
phosphorylation by AMPK. Nowadays, AMPK is considered as potential target for the 
development of an anti-diabetic drug [211]. Our laboratory showed recruitment of LKB1 
to AMPK upon PB treatment [212]. LKB1 was described to be responsible of the anti 
diabetic action of metformin. It is worth of interest to test if some of the pleiotropic effect 
of PB can be explained by activation of the LKB1-AMPK-CAR cascade.  
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Figure 1  PB represses PEPCK in primary human and mouse hepatocytes 
hepatocytes in primary culture were cultured in glucose free medium and exposed for 16h to 0.5, 1 and 2 
mM of phenobarbital (PB), 0.5 and 1 mM AICAR or 5 uM of Compound C (Comp C) or a combination of 
AICAR and comp C. PEPCK (A, C) and CYP2B6 (B) mRNA were quantified by RT-PCR and 
standardized to 18S.  
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Figure 2 Liver specific deletion of AMPKα1 
and   α2 subunits in mice blunts the 
repression of PEPCK by PB 
 
Wild type mice and mice with liver specific deletion of 
AMPKα1 and α2 subunits (AMPKα1lsα2) were injected 
i.p. with saline (□, open bars) or PB 100 mg/kg (■, black 
bars) and sacrificed 16h later as described under Materials 
and Methods. PEPCK mRNA (A) was quantified by RT-
PCR and standardized to GAPDH. Results represent 
means of five different mice ± S.D. with each 
determination done in triplicates. (*,p<0.05). Mouse 
hepatocytes prepared from wild type and AMPKα1lsα2 
KO mouse liver were cultured in Williams E glucose free 
medium and exposed for 12h to 500 uM phenobarbital 
(PB) or 5 uM of Compound C (comp C). As indicated 
PEPCK mRNA (B) quantified by RT-PCR and 
standardized to GAPDH 
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Figure 3  CAR mediates the inhibition of PEPCK mRNA by phenobarbital  
Primary mouse hepatocytes from wild type (□, open bars) or from mice with a total deletion of constitutive androstane receptor (CARKO) (■, black bars) were 
exposed for 8h to 500 uM phenobarbital (PB), 1 uM deamethasone (dex), 10 uM dibutyryl-cAMP (cAMP), 10 nM insulin or 5 uM Compound C (CompC). PEPCK 
mRNA (A) and G6Pase (B) were quantified by RT-PCR and standardized to GAPDH. Expression of mouse AMPKα1, AMPKα2 and β actin were shown by western 
blot (C) after 4 h treatment with 500 µM PB. Glucose concentration was measured in the medium of wild type and CARKO hepatocytes cultured in glucose free 
medium and treated for 16h with PB 500 uM or AICAR 500 uM or metformin  1 mM (Metf). 
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 Figure 4: PGC-1α and CAR co transfection enhance PEPCK transactivation  
 
The -467+69 PEPCK-LUC reporter and pcDNA3hCAR were cotransfected with pEBG2T-hFOXO1 in CV-
1 cells (A). Cell extracts were analyzed for luciferase activity normalized against β-galactosidase activity. 
Fold induction indicates relative luciferase activity standardized against control cells infected with 467+69 
PEPCK-LUC reporter alone. The data represent means of triplicate measurements from a representative 
experiment, and error bars indicate SD. CV-1 cells were co-transfected with Gal4 DNA binding domain 
fused to hCAR LBD (pMhCAR LBD) and human PGC-1α, the reporter construct Gal4 response element 
(Gal-RE), and pRSVβ-galactosidase (B). Cell extracts were analyzed for luciferase activity normalized 
against β-galactosidase activity 
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Figure 5  Immunoprecipitaiton of human CAR and AMPKα2 
Immunoprecipitation of HA-hCAR by anti-HA antibody and of myc-AMPKα2 by anti-myc antibody (A). Cofactor assay: AMPK α2 subunit binds to hCAR (B).  
HAhCAR pulled down with AMPK α1 subunit (C). human CAR and AMPK α2 colocalized in primary human hepatocytes (D). AMPK represses PEPCK 
transactivation by hCAR and PGC-1α
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Figure legends 
 
Figure 1:  PB represses PEPCK in primary human and mouse hepatocytes 
 
Human hepatocytes in primary culture were cultured in glucose free medium and exposed 
for 16h to 0.5, 1 and 2 mM of phenobarbital (PB), 0.5 and 1 mM AICAR or 5 uM of 
Compound C (Comp C) or a combination of AICAR and comp C. PEPCK (A, C) and 
CYP2B6 (B) mRNA were quantified by RT-PCR and standardized to 18S as described 
under Materials and Methods. Results are means of three different donors ± S.D. with 
each determination done in triplicates Mouse hepatocytes in primary culture were 
cultured in DMEM containing 5 mM glucose and exposed for 12h to 0.5 and 1 mM 
AICAR or 5 uM of Compound C (Comp C) (D) PEPCK mRNA was quantified by RT-
PCR. Results are means of three different mice ± S.D. with each determination done in 
triplicates. (*,p<0.05; **,p<0.01). Values obtained with PB, AICAR and CompC are 
compared with values obtained from untreated cells. 
 
Figure 2: Liver specific deletion of AMPKα1 and α2 subunits in mice blunts the 
repression of PEPCK by PB. 
 
Wild type mice and mice with liver specific deletion of AMPKα1 and α2 subunits 
(AMPKα1lsα2) were injected i.p. with saline (□, open bars) or PB 100 mg/kg (■, black 
bars) and sacrificed 16h later as described under Materials and Methods. PEPCK mRNA 
(A) was quantified by RT-PCR and standardized to GAPDH. Results represent means of 
five different mice ± S.D. with each determination done in triplicates. (*,p<0.05). Mouse 
hepatocytes prepared from wild type and AMPKα1lsα2 KO mouse liver were cultured in 
Williams E glucose free medium and exposed for 12h to 500 uM phenobarbital (PB) or 5 
uM of Compound C (comp C). As indicated PEPCK mRNA (B) quantified by RT-PCR 
and standardized to GAPDH. Results are means of three different mice from each 
genotype ± S.D. with each determination done in triplicates. (*,p<0.05; **,p<0.01). 
Values obtained with PB or compC or their combinations are compared with values 
obtained from untreated cells. Values obtained with compC in the AMPKα1lsα2 KO 
mice are compared to the untreated cells from the same group (#,p<0.05). Human 
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hepatocytes in primary culture were cultured in medium containing 5 mM glucose and 
infected with adenovirus containing β-galactosidase (Ad βGal) (□, open bars) or a 
constitutively active form of AMPKα2 subunit (Ad AMPKcaα2) (■, black bars) as 
described under Materials and Methods. Twenty four hours after infection cells were 
exposed for 16h to 1 uM dexamethsaone and 10 uM dibutyryl-cAMP, 500 uM AICAR or 
500 uM phenobarbital (PB). PEPCK (C) mRNA was quantified by RT-PCR and 
standardized to 18S. Results are compared with values from cells not exposed to drugs 
and infected with Ad βGal (*,p<0.05; **,p<0.01). Values obtained with cells infected 
with Ad βGal are compared to cells infected with Ad AMPKα2 for each drug treatment 
(#,p<0.05; §§,p<0.01; ¦,p<0.05). 
 
Figure 3: CAR mediates the inhibition of PEPCK mRNA by phenobarbital. 
 
Primary mouse hepatocytes from wild type (□, open bars) or from mice with a total 
deletion of constitutive androstane receptor (CARKO) (■, black bars) were exposed for 
8h to 500 uM phenobarbital (PB), 1 uM deamethasone (dex), 10 uM dibutyryl-cAMP 
(cAMP), 10 nM insulin or 5 uM Compound C (CompC). PEPCK mRNA (A) and G6Pase 
(B) were quantified by RT-PCR and standardized to GAPDH. All values obtained with 
drugs exposure are compared to values from cells from wild type animals and not 
exposed to drugs (**,p<0.01). All values obtained with the combination of Dex and 
cAMP are compared to the values obtained from Dex cAMP wild type treated cells 
(##,p<0.01). Primary mouse hepatocytes from wild type and CARKO animals were 
cultured in serum free medium for 24h. Results are means of three different mice ± S.D. 
with each determination done in triplicates. (*, p<0.05). Expression of mouse AMPKα1, 
AMPKα2 and β actin were shown by western blot (C) after 4 h treatment with 500 µM 
PB. Glucose concentration was measured in the medium of wild type and CARKO 
hepatocytes cultured in glucose free medium and treated for 16h with PB 500 uM or 
AICAR 500 uM or metformin  1 mM (Metf). 
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Figure 4: PGC-1α and CAR co transfection enhance PEPCK transactivation  
 
The -467+69 PEPCK-LUC reporter and pcDNA3hCAR were cotransfected with 
pEBG2T-hFOXO1 in CV-1 cells (A). Cell extracts were analyzed for luciferase activity 
normalized against β-galactosidase activity. Fold induction indicates relative luciferase 
activity standardized against control cells infected with 467+69 PEPCK-LUC reporter 
alone. The data represent means of triplicate measurements from a representative 
experiment, and error bars indicate SD. CV-1 cells were co-transfected with Gal4 DNA 
binding domain fused to hCAR LBD (pMhCAR LBD) and human PGC-1α, the reporter 
construct Gal4 response element (Gal-RE), and pRSVβ-galactosidase (B). Cell extracts 
were analyzed for luciferase activity normalized against β-galactosidase activity. The data 
represent means of triplicate measurements from a representative experiment, and error 
bars indicate SD. The -467+69 PEPCK-LUC reporter and pcDNA3hCAR were 
cotransfected with human PGC-1α in CV-1 cells, treated with 500 uM AICAR for 24h 
(C) 
 
Figure5: Immunoprecipitaiton of human CAR and AMPKα2 
   
Immunoprecipitation of HA-hCAR by anti-HA antibody and of myc-AMPKα2 by anti-
myc antibody (A). CV-1 cells were co-transfected with Gal4 DNA binding domain fused 
to hCAR LBD (pMhCAR LBD) and human AMPKα2, the reporter construct containing 
Gal4 response element (Gal-RE), and pRSVβ-galactosidase (B). Incubation of 
recombinant histidine tagged AMPKα1 subunit (HIS-AMPKα1) with protein lysates 
expressing an adenovirus encoding for HA tagged hCAR (Ad-HAhCAR). Binding 
between AMPKα1 and HAhCAR is shown by the co-elution profile detected by western 
blot (C). HIS-AMPKα1 is detected with an antibody against AMPKα1 and Ad-HAhCAR 
is detected with an antibody against HA. Primary human hepatocytes infected with 
adenovirus expressing EGFP human CAR (D) (pEGFP-hCAR). Exogenous EGFP-hCAR 
was detected with an anti-GFP antibody and endogenous AMPKα2 was detected with an 
anti AMPKα2 antibody. The -467+69 PEPCK-LUC reporter, pcDNA3hCAR, hPGC-1α 
were cotransfected with AMPKα1, AMPK dead kinase α1 subunit (AMPKα1 KD) or 
AMPKα2 in CV-1 cells (E). Cell extracts were analyzed for luciferase activity 
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normalized against β-galactosidase activity. The data represent means of triplicate 
measurements from a representative experiment, and error bars indicate SD. 
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Supplemental data 
CAR and AMPK interaction 
 
We previously showed that AMPKα subunit binds to human CAR. However, the domains 
by which CAR and AMPK interacts remain unclear. Furthermore, the nature of this 
interaction is also complex because it may involve a simple protein-protein connection or 
a “hit and run” phosphorylation process. We then decided to preform competition 
experiments, where a known substrate of AMPK, SAMS peptide is challenged with a 
peptide contained in the ligang binding domain of human CAR.The CAR peptide is 
depicted in figure 1. We assessed AMPK activity by measuring SAMS peptide 
phosphorylation by a recombinant AMPK as described in material methods. 
As shown in figure 2A, AMPK reaches the maximum of its acitvity in the presence of 
100 uM of SAMS. Interestingly, 50 uM of the CAR T248 peptide blunt this activation, 
suggesting that the T248 peptide may compete with SAMS peptide for phosphorylation 
by AMPK. It worth noting, that the T248 peptide alone does not increase the AMPK 
activity. Increassing amount of T248 peptide dose dependently inhibits SAMS peptide 
phosphorylation by AMPK (Figure 2B). Indeed, 10 uM of T248 peptide completely 
abolished AMPK activity on. 
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Figure 1  Human CAR Ligand Binding Domain 
Figure 2  Competition between SAMS and hCAR T248 peptides 
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In order, to test the specificity of the competition between the two peptides, we incubated 
SAMS with a control peptide from a non AMPK protein target. The activity of AMPK 
was not disturbed by the control peptide, whereas T248 blunted AMPK activity. This 
result suggests that CAR T248 peptide may specifically compete with SAMS peptide for 
the AMPK phosphorylation. 
Finally, we used the full ligand bind domain of CAR (LBD) as competitor for SAMS 
phosphorylation. In picomolar range, human CAR LBD can compete with SAMS (Figure 
3A). When CAR LBD and SAMS are incubated together, the AMPK activity is decerased 
by ~ 30 % (Figure 3B). Taken together, these results demonstrate that the human CAR 
ligand binding domain may be a potential target for the AMPK. 
 
 
Figure 3: hCAR LBD and SAMS competition 
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Discussion 
CAR as a glucose sensor 
We have previously shown (cf Results part I) that CAR expression is induced during 
fasting and more specifically in the absence of glucose in human hepatocytes in primary 
culture (cf results I). A previous study by Bauer et al. also showed an increase of CAR 
mRNA expression in the liver of mice fasted for 24 hours [213]. By contrast, in this 
study, 24 hours of high carbohydrate diet did not affect CAR mRNA expression. 
Additionally, in the absence of glucose insulin represses CAR mRNA in human 
hepatocytes. This may indicate that CAR is regulated somehow by the fasting-feeding 
transition, when dramatic changes in insulin concentration occur. The G-6-Phosphatase 
and PEPCK promoters are known to be insulin targets and both contain so-called insulin-
responsive sequences [214]. These sequences [T(G/A)TTT] have been functionally 
characterized, and several transcription factors that bind to these regions have been 
identified. It is thus possible that the CAR promoter contains such sequences and 
consequently is directly regulated by transcription factors induced by insulin. However, 
to discriminate between the glucose and the insulin effect, CAR expression and activity 
should be assessed in vivo for instance using hyperglycaemic-hyperinsulinemic clamps 
[215-217]. 
Interestingly, a recent study reported that CAR mRNA and protein levels were increased 
in diabetic db/db mouse livers [218]. However, the same group also demonstrated that 
CAR expression was markedly impaired in the livers of genetically obese Zucker rats 
which seemed to result in the reduced expression of CYP2Bs in these rats [219]. This 
discrepancy is very intriguing because both animals have mutation in the leptin receptor 
gene and show similar characteristics of hyperphagia, hyperglyceamia, hyperlipidemia 
and obesity [220]. As db/db mice and Zucker rats have mutations at a different position 
of the leptin receptor gene [221-223], this may explain the discrepancy in CAR 
expression. 
During fasting, the expression of genes encoding for proteins involved in glucose 
transport and phosphorylation in the liver is significantly lower in the liver of mice 
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lacking CAR, which indicates that CAR may promote glucose uptake and subsequently 
enhance the glycolytic pathway. However, this result is very curious, because why would 
CAR upregulate already low levels of expression of these genes during fasting ? It is 
possible that CAR function consists of providing a minimum of energy required for drug 
metabolism to occur. Furthermore, since GLUT2 [224] and CAR expression are both 
regulated by the fasting/feeding transition in Shepatocytes, one could assume that CAR 
may be the mediator of insulin action on the regulation of GLUT2 expression during 
nutritional stress. 
It is well established that a decrease of glyceamia during fasting leads to glucagon-
mediated increase of cAMP levels in the liver [225]. Consequently, Ding et al., 
hypothesized that the activation of CAR during fasting is a cAMP-dependent 
phenomenon. They provided evidence that both CAR target genes, including Cyp2b10, 
Oatp2, Sult2a1, and Ugt1a1, as well as the CAR gene itself, are induced in mouse liver 
during fasting. Treatment of primary mouse hepatocytes with the β-adrenergic agonist 
epinephrine induces both CAR and its target genes. This effect is mimicked by the cAMP 
analogue 8-Br-cAMP [184]. The authors also demonstrated by gene reporter assays that 
the CAR promoter is regulated by the hepatocyte nuclear factor 4α (HNF4α) (figure 1). 
Additional fasting experiments performed using liver-specific HNF4α -knock-out 
(HNF4α-KO) mice demonstrated that HNF4α is required in vivo for both basal and 
fasting-inducible CAR gene expression. Another interesting study by Pascussi et al. 
investigated the effect of HNF4α isoforms (HNF4α1 and HNF4α7) on the human CAR 
promoter [226]. HNF4α7 is highly expressed in the pancreas and HNF4α1 is essentially 
expressed in the liver and both HNF4α isoforms bind to CAR promoter with similar 
affinity. However, HNF4α1 strongly enhanced hCAR promoter activity whereas 
HNF4α7 repressed the HNF4α1-mediated transactivation of the hCAR promoter. 
Briancon and al. also confirmed in vivo the specificity of HNF4α1 in the regulation of the 
CAR promoter [227]. Furthermore, the fasting- and cAMP-inducible coactivator PPARγ 
coactivator 1α (PGC-1α) coactivates HNF4α on the CAR promoter. The extent to which 
chronic overexpression of PGC-1α in liver such as it occurs during caloric restriction may 
contribute to CAR induction remains to be investigated. The data presented by the 
authors cannot rule out the possibility that other PGC-1α-independent mechanisms also 
are involved in the activation of CAR during fasting. For example, a recent study shows 
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that the coactivator PPAR-binding protein (PBP) is critical for the induction of CAR 
target genes by xenobiotics [228], but these data do not address a role for PBP protein in 
the activation of CAR during fasting. Another study describes the coactivator PBP to be 
essential for nuclear translocation of CAR [229], but the role of this interaction in fasting 
has not yet been studied. Adenoviral expression of both PBP and EGFP-CAR restored 
phenobarbital-mediated nuclear translocation of exogenously expressed CAR in PBP-
null livers and in PBP-null primary hepatocytes. Unfortunately, functionnal interaction of 
PBP and CAR has not been assessed. It is possible that the xenobiotic response of CAR is 
different from its metabolic response and is produced through interaction with distinct 
cofactors, such as PGC-1α, during fasting. The respective CAR-cofactor complexes 
might then function to regulate the expression of different groups of genes in response to 
metabolic versus xenobiotic stress. The positive regulation of CAR expression by HNF4α 
and PGC-1α during fasting highlights the complexity of the role played by CAR since its 
activation by phenobarbital leads to a repression of gluconeogenic genes. This finding 
contributes to the concept of different mechanisms involved in fasting and drug 
induction. 
Pascussi et al. also reported that glucocorticoid agonists, such as dexamethasone, 
prednisolone, or hydrocortisone, specifically increase human CAR mRNA expression. 
Additionally, dexamethasone increases both basal and phenobarbital-mediated nuclear 
translocation of CAR protein in human hepatocytes. The up-regulation of CAR mRNA 
and protein in response to dexamethasone explains the synergistic effect of this 
glucocorticoid on phenobarbital-mediated induction of CYP2B genes [230]. Moreover, 
another study describes the binding of the glucocorticoid receptor to the distal region of 
the human CAR promoter in cultured hepatocytes [231]. On the basis of cotransfection 
experiments, mutagenesis, and gel shift assays, the authors identified a glucocorticoid 
response element at -4447/-4432, which was recognized and transactivated by the human 
glucocorticoid receptor. Thus, we speculate that CAR expression in vivo increases in 
situations where glucocorticoid hormone levels are high, e.g. in stress conditions, during 
the peak of the corticosterone circadian rhythm or during fasting [232, 233]. 
Unfortunately, there exist no in vivo data in support of the role of endogenous 
glucocorticoids such as cortisol in the induction of CAR mRNA during fasting. 
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Nonetheless, similary to HNF4α and PGC-1α, GR is a crucial factor in the sustained 
induction of PEPCK during prolonged fasting and is a positive regulator of CAR. 
Inflammation and/or infection are frequently associated with a reduced capacity of liver 
to metabolize xenobiotics/drugs [234]. Cytokines and bacterial endotoxins are likely to 
be responsible for this effect [235], and were shown to reduce CAR gene expression in 
primary human hepatocytes [236, 237]. Cytokines, oxidative stress, and chemicals are 
known to trigger NFκB activation [238] and this pro-inflammatory factor has been shown 
to bind and inactivate GR [239]. Thus, activation of NFkB in human hepatocytes leads to 
inhibition of GR transcriptional activity, and may cause the downregulation of CAR. The 
mechanism by which NFκB inhibits CAR transcription is unknown. A model for the 
induction of CAR mRNA during fasting is depicted in Figure 1.  
In experiments where CARKO mice were fasted and refed upon a high carbohydrate diet, 
a lower expression of lipogenic genes was observed. This corroborates with lower levels 
of triglycerides in the liver of CARKO mice fed with a high carbohydrate diet for 12 
weeks (unpublished data). Suprisingly, no difference in the amount of white adipose 
tissue has been observed between CARKO and normal mice. Interestingly, CARKO 
animals did not loose significantly more weight than normal animals during the 
experiment. This result is very suprising since Maglich et al., demonstrated that CARKO 
animals lost more weight than wild type animals under caloric restriction. More 
importantly, the data of Maglich and co-workers indicate that the weight loss observed in 
the CARKO animals was normal loss of stored fat from adipose tissue and not from lean 
mass [109]. The authors explained this result, in part, by the role of CAR in the 
regulation of thyroid hormone metabolism (cf introduction). However, thyroid hormone 
action alone is not sufficient to explain the role of CAR in the control of weight. 
Although their data demonstrate that CAR is required for the downregulation of thyroid 
metabolism upon caloric restriction, it was notable that a partial response was still 
observed in the CAR knockout mice, indicating that other mechanisms contribute to the 
process. The discrepancy between the studies may be attributed to the differences in the 
experimental conditions. We fed mice with a high carbohydrate /low fat diet at 15 MJ/kg 
which can be converted to approximatively 11.5 kcal/day/mouse, whereas the authors 
used a diet of 8 kcal/day/mouse. Consequently, the high carbohydrate diet used in our 
study might not provide enough energy to be assimilated as an energy-rich diet. 
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Nevertheless, further investigations are needed to find out how carbohydrates regulate 
weight in a CAR dependent manner and what the molecular mechanisms as well as 
factors underlying CAR regulation during nutritionnal stress may be. 
Fasting Glucagon 
/Epinephrine 
cAMP PKA 
signaling 
CREB 
P 
PGC-1α 
PGC-1α 
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Figure 1: Model for the induction 
of CAR and CAR target 
genes by cAMP in mouse 
liver during caloric 
restriction or fasting. 
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 89 
Role of CAR in the regluation of PEPCK 
As we previously described, PEPCK is a key protein in the regulation of hepatic glucose 
production during fasting (cf introduction). Suprisingly, our data indicate that basal 
expression of PEPCK mRNA is unaffected in livers of mice lacking CAR which suggests 
that endogenous CAR does not seem to be a constitutive repressor of PEPCK. 
Furthermore, the transfection of increasing amount of human CAR alone or with PGC-1α 
induces PEPCK promoter activity and mRNA in hepatoma cells. It has also been 
confirmed recently that the transfection of human CAR did not repress PEPCK mRNA in 
human hepatocytes [240]. The authors discovered a new variant of human CAR 
expressed from internal protein translation start sites. The resulting CAR protein lacks 
the N-terminal DNA-binding domain (DBD) of the receptor, yielding a ∆CAR variant 
with unique biological function. Although ∆CAR maintains full retinoid X receptor alpha 
(RXRα) heterodimerization capacity it is inactive on classical CAR-inducible direct 
repeat (DR)-4 elements, but efficiently transactivates a DR-1 element derived from the 
endogenous PPAR-inducible acyl-CoA oxidase gene promoter. The authors propose a 
new model of CAR DBD-independent transactivation, where only the RXRα portion of 
the CAR-RXRα heterodimer binds directly to DNA. It might explain  the regulation of 
PEPCK expression by CAR since it has been shown that CAR competes with HNF4α for 
binding to a DR-1 site in the PEPCK promoter [40]. Taken together, these studies 
highlight a new role of CAR where it can serve as a cofactor for other transcription 
factors. 
It is well established that protein kinase A (PKA) mediates the hormonal control of 
gluconeogenesis during fasting [241-243]. Our data indicate an additive effect of PKA 
and CAR on PEPCK promoter activity. This effect explains at least partially the role of 
CAR mRNA induction during fasting. However, it remains to be determined in which 
physiological context and how CAR and PKA cooperate in the regulation of PEPCK. A 
recent study shows that phosphorylation/dephosphorylation of serine 202 regulates 
subcellular localization of CAR [244]. Therefore, CAR may be the target of PKA and it 
may modulate CAR-cofactor interactions through alterations in phosphorylation status of 
co-factor proteins, CAR, or both. But, these data should be interpreted with caution 
         
 90 
because the serine 202 does not match with a PKA phosphorylation site and the 
experimental conditions were far from the in vivo situation. 
The CAR-mediated transactivation of PEPCK is blunted by phenobarbital but not by the 
CAR ligand CITCO. It is now clear that pharmacological activation of CAR by PB may 
not necessarily reflects the constitutive endogenous activation of CAR or its direct 
activation by a ligand. On one hand, CAR dose-dependently induces PEPCK mRNA and 
on the other hand, PB represses PEPCK in a CAR dependent manner. Since no 
endogenous ligand has yet been identified, it is very difficult to distinguish between the 
endogenous role of CAR and its pharmacological activation by PB. The difference 
between fasting and PB-mediated CAR activation can be attributed to interaction with 
specific cofactors, such as PGC-1α, during fasting. This hypothesis is supported by a co-
factor assay showing that PB blunts the interaction between CAR and PGC-1α (cf 
Results Part). Although CAR and PGC-1α clearly interact, the physiological relevance of 
such interaction remains unknown. In collaboration with Christoph Handschin and Bruce 
Spiegelman we could show that PGC-1α knock out mice retain cyp2b10 PB-mediated 
induction [245] speeking againt an essential role of this coactivator in drug metabolism.  
PGC-1α is not essential in the regulation of PEPCK since transcription of the PEPCK 
gene can occur in the absence of PGC-1α (but at a lower level) suggesting that it serves 
as a "transcriptional amplifier" for this gene [246]. PGC-1α promotes transcription by the 
assembly of a transcription factor complex. This interaction has been proposed to cause a 
conformational change in PGC-1α, which permits the binding of other cofactors such as 
SRC-1 and CBP/p300 [247]. If the role of PGC-1α in the coactivation of CAR on the 
PEPCK promoter can be replaced by another cofactor is not known yet, but it is clear that 
cofactors are very redundant in their function. 
Stafford and coworkers have suggested that SRC-1 interacts with HNF-4α and with 
COUP-TFII, both of which are required for the maximal induction of PEPCK gene 
transcription by glucocorticoids [164]. Transfection, analysis demonstrated that mouse 
CAR interacts with SRC-1 [248], while another study reported that SRC-1 enhances both 
constitutive and xenobiotic-induced CAR-mediated transactivation via the CYP2B1 PB-
response element in rat transfected primary hepatocytes [249]. Furthermore, transient 
transfection assays with increasing amounts of SRC-1 reveal that amino acid at position 
176 could regulate the interaction of mCAR with SRC-1 in the presence and absence a 
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ligand [250]. These data strongly suggest that SRC-1 contributes to the translocation and 
activation of CAR during CYPs induction. However, no evidence supports a role of a 
SRC-1-CAR interaction in the regulation of gluconeogenesis. Nevertheless, the 
recruitment of specific co-factors by CAR may then explain the dual role of CAR in the 
regulation of PEPCK. The nutritional context may influence the affinities between CAR 
and other transcription factors involved in the regulation of PEPCK.  
A variety of other agents, in addition to insulin and glucose, repress PEPCK gene 
transcription [134]. In fact, a number of changes in glucose metabolism occur during 
infection, neoplastic growth, or tissue damage. Hypoglycemia is a major complication in 
the septic shock syndrome and is believed to result from the repression of PEPCK 
transcription by the concerted actions of TNF-α, IL-1, and IL-6 in the liver [251, 252]. 
Waltner-Law et al. reported that the p65 subunit of NF-κB represses the increase of 
PEPCK gene transcription mediated by glucocorticoids and cAMP in a concentration-
dependent manner in H4IIE cells. Further analysis suggested that p65 represses PEPCK 
gene transcription through a protein-protein interaction with the coactivator, CBP [253]. 
Thus another possibility that may link NF-κB to CAR is competition for CBP/P300 or 
SRC-1 in the regulation of PEPCK. However, a recent study does not support this 
finding. The authors showed that moderate inhibition of NF-κB improved glucose 
tolerance through decreased gluconeogenesis associated with reduced PGC-1α gene 
expression in db/db mice, and suggest that inhibition of NF-κB activity in liver is a 
potentially suitable strategy for the normalisation of blood glucose concentration in type 
2 diabetes [254]. Further studies are needed to confirm the role of NF-κB in the 
regulation of gluconeogenesis and the possible link between CAR and NF-κB signaling 
cascade. 
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Figure 2: Hypothetic model for the regulation of PEPCK promoter by phenobarbital 
 
A. In the absence of PB, PGC-1α coactivates CAR on PEPCK promoter and weak competition between 
CAR and HNF-4α occurs.  B. Once activated by PB, CAR accumulates in the nucleus and binds to AMPK 
thereby preventing PGC-1α from its recruitment to the PEPCK promoter. 
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The CAR-AMPK connection 
The data presented in this thesis demonstrate that AMPK and CAR are both necessary for 
the PB-mediated repression of PEPCK. Furthermore, we provide evidence for direct 
interaction between CAR and the AMPKα catalytic subunit by coimmunoprecipitation 
and pull-down experiments. Our group also reported that AMPK plays an essential role in 
the induction of CYP2B and CYP3A forms by phenobarbital, and that among several 
CAR and PXR agonists (including notably rifampicin, CITCO, and TCPOBOP), only 
phenobarbital increased the AMP/ATP ratio and activated AMPK [255, 256]. AMPK was 
not necessary for controlling the nuclear translocation of CAR, although CAR was 
concentrated in nuclear speckles in the hepatocytes of AMPKα1/α2 (−/−) mice, whereas 
its accumulation was homogeneous in cell nuclei from wild-type animals. Since AMPK 
and CAR co-localize in the nucleus of human hepatocytes in primary culture, CAR may 
be a target of AMPK in the PB-mediated regulation of CYPs and PEPCK. Preliminary 
experiments in our group indicated that a CAR peptide containing a consensus AMPK 
target sequence competed for phosphorylation when incubated with SAMS peptide, a 
known synthetic substrate of AMPK. However, this finding must be confirmed in an in 
vivo situation and we cannot yet exclude definitively that CAR is not phosphorylated by 
AMPK. Hosseinpour et al. reported that the dephosphorylation of Ser-202 is required in 
the regulation of the xenobiotic-dependent nuclear translocation of mCAR [244], but the 
phosphorylation as well as the putative up-stream kinase(s) have not yet been evidenced. 
Furthermore, the serine-202 does not match with an AMPK consensus site of 
phosphorylation. 
We also show in this thesis that exogenous expression of CAR blunts the PB-mediated 
activation of AMPK in mouse hepatocytes in primary cultures. AMPK is activated by PB 
and more importantly was shown to be essential in the PB-mediated regulation of CYPs. 
Furthermore, our group showed that the phosphorylation of AMPK is required in the 
regulation of CYPs [255] whereas kinase activity seems to be facultative in the repression 
of PEPCK. Therefore, it is possible that a protein-protein interaction between CAR and 
AMPK may be the master signal in the regulation of PEPCK. Since AMPK expression is 
lower in hepatocytes lacking CAR, another possibility might be that exogenous CAR may 
interfere with the complex interplay of proteins, thereby regulating the expression of 
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AMPK and subsequently its activation. Finally, PXR is known to regulate several CAR 
target genes, thus it is not excluded that in the absence of CAR, the role of PXR may be 
extended to the regulation of AMPK activity.  
Interestingly, the expression and consequently the phosphorylation of acetyl-coA 
carboxylase, a known AMPK target is lower in the hepatocytes from CARKO animals 
suggesting a lower AMPK activity in the liver of these mice. This result corroborates the 
lower expression of acc-1, acc-2 and fas during the fasting refeeding experiment and with 
a lower accumulation of triglycerides, whereas it does not correlate with the expresssion 
of acc-1, acc-2 and fas during the high carbohydrate experiment. However, Savage et al. 
suggested that both acc-1 and acc-2 are involved in regulating fat oxidation in the liver, 
whereas only acc-1 synthesizes malonyl-CoA for fat synthesis [257-259]. Altogether, 
these findings are consistent with a role of CAR in the regulation of lipid metabolism via 
acetyl-coA carboxylase isoforms 1 and 2. 
Malonyl CoA is a regulator of carnitine palmitoyl transferase 1 (CPT-1), the enzyme that 
controls the transfer of long chain fatty acyl-CoA into mitochondria where it is oxidized. 
The formation of malonyl-CoA is regulated acutely (in minutes) by changes in the 
activity of acetyl CoA carboxylase, the enzyme that catalyzes malonyl CoA synthesis. An 
increase in the concentration of malonyl-CoA leads to the inhibition of CPT-1 activity 
and subsequently to the inhibition of beta oxidation of fatty acids. A decrease in ACC-1 
and/or 2 phosphorylation leads to an increase in malonyl-CoA synthesis and ultimately to 
the inhibtion of CPT-1. Whether the CAR-mediated regulation of ACCs is reflected in 
malony-CoA synthesis and activation of CPT-1 is not known. Furthermore, our study did 
not discriminate between ACC-1 and ACC-2 isoforms. Thus, the relative importance of 
each isoforms in the regulation of lipogenesis and fatty acid oxidation may complicate the 
comprehension of the role of CAR. Previous reports described that the repeated treatment 
of rats with phenobarbital downregulates a number of genes involved in energy 
metabolism, including CPT-1. Additionally, Ueda et al. showed by cDNA microarray 
analysis that PB-mediated downregulation of CPT-1 was CAR dependent in mouse liver 
[14].  However, a recent study indicated that the serum concentration of total ketone 
bodies was increased after seven days of PB treatment [260]. It is worth noting that all 
these data have to be interpreted with caution, since no experiments demonstrate CAR as 
a regulator of beta oxidation of fatty acids or ketogenesis in the liver.  
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Although ACC is a known target of AMPK, in CARKO hepatocytes, the higher 
expression of AMPK α1 subunit does not correlate with a stronger phosphorylation of 
ACC. This finding indicates that CAR may regulate ACC expression and activity 
independently of AMPK α1 subunit. Interestingly, a recent study reported that caloric 
restriction decreased threonine-172-phosphorylated AMPKα levels in the liver, and the 
levels of ACC phosphorylation did not alter in parallel with the AMPK phosphorylation 
level, particularly in the liver [261]. Another study showed that the expression of ACC 
and its phosphorylation increased independently of AMPK activation upon high 
carbohydrate diet [262]. Altogether, these results suggest that other AMPK independent 
mechanisms are involved in the regulation of ACCs. Moreover, the activities of both 
AMPK α1 and α2 subunits and their relative contribution to the phosphorylation of ACC 
in the liver have not yet been studied.  
 
 
 
 
 
 
 
 
 
 
Figure 3: Role of CAR in hepatic metabolism 
 
In the fed state insulin represses CAR mRNA expression which may indirectly impair the regulation of 
glucose homeostasis and lipid metabolism. 
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Nuclear receptor cross-talk and glucose homeostasis 
A major breakthrough in bile acids (BAs) metabolism came with the demonstration that 
BAs bind to and activate the farnesoid X receptor (FXR), an adopted member of the 
nuclear receptor family [263-265]. The physiological role of FXR is to protect liver cells 
from the deleterious effects of BA overload by decreasing their endogenous production 
and accelerating their biotransformation and excretion, thereby acting as an intracellular 
bile acids sensor [266]. Despite some unresolved discrepancies, several sets of data are 
also in favor of a role for FXR in the control of gluconeogenic gene expression. Some 
results indicate that FXR might decrease PEPCK expression through the induction of 
SHP, which inhibits the activation of the PEPCK promoter by HNF-4α and Foxo1 in 
response to BAs treatment [267], whereas other in vitro data showed that BAs decrease 
the activity of HNF-4α, which is a positive regulator of PEPCK gene expression, in an 
FXR-independent manner [268]. Other studies demonstrated that FXR activation by an 
agonist induces PEPCK expression, leading to an increased glucose output in rodent 
primary hepatocytes in vitro [269]. Interestingly, SHP has been shown to bind to and 
inhibit the transcriptional activity of CAR [270]. Although, the interaction between CAR 
and FXR has never been evidenced, previous reports indicated that several sequences 
known to be responsive elements in the promoter of CAR and PXR target genes are 
shown to be targets of FXR [94, 271]; we might then speculate that CAR and FXR may 
cross-talk via SHP to regulate PEPCK during nutritional stress. 
AMPK in hepatic glucose metabolism 
The activation of AMPK suppresses the transcription of PEPCK and G6Pase in hepatoma 
cells [205], providing clues for the role of AMPK in gluconeogenesis. Furthermore, 
AMPK α2 liver-specific knockout mice are glucose intolerant and display fasting 
hyperglycemia, presumably because of elevated gluconeogenesis associated with 
increased PEPCK and G6Pase activity [272]. Recent data have provided evidence that 
inhibition of gluconeogenesis by AMPK involves a transcriptional coactivator, the 
transducer of regulated CREB activity 2 (TORC2) [273]. Glucagon and fasting induce 
hepatic TORC2 nuclear translocation, which enhances CREB-dependent transcription of 
gluconeogenic genes such as PGC-1α. Conversely, AMPK activation causes TORC2 
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phosphorylation and sequesters the coactivator in the cytoplasm, thus blunting 
gluconeogenesis. Deletion of hepatic LKB1, an upstream kinase of AMPK, abolishes 
AMPK activation and leads to nuclear accumulation of TORC2, which in turn drives 
gluconeogenesis [274] (Figure 4). Consistently, liver LKB1 knockout mice on a high-fat 
diet exhibit fasting hyperglycemia and glucose intolerance and are unresponsive to 
metformin treatment [274]. Interestingly, our group demonstrated that phenobarbital 
promotes the formation of an LKB1-AMPK complex, resulting in the phosphorylation of 
LKB1 which in turn leads to the phosphorylation of AMPK [212]. Whether this 
mechanism can be generalized to mammalian species and extended to the regulation of 
gluconeogenesis is presently unknown. Nevertheless, this finding is consistent with the 
previously reported observation that PB lowers blood glucose in patients with noninsulin-
dependent diabetes, as mentionned above (introduction). 
Inoue et al. cloned and characterizated a novel zinc finger transcription factor referred to 
as AICAR response element binding protein (AREBP) [275]. AREBP is phosphorylated 
at Serine 470 by AMPK. Transient transfection experiments indicate that wild-type 
AREBP represses PEPCK gene expression. However, the authors did not provide any 
evidence for the role of AREBP in the in vivo regulation of PEPCK. Furthermore, 
whether phenobarbital induces the AMPK-mediated phosphorylation of AREBP is 
presently unknown.  
Many of the studies validating AMPK stimulation as a potential target for the treatment 
of type-2 diabetes, obesity and the metabolic syndrome have utilized AICAR as a tool to 
induce AMPK activation. Since AICAR is metabolized to ZMP, an AMP mimetic, it 
clearly has additional effects that are independent of AMPK activation. In both rat 
hepatocytes [276] and mice in vivo [277], AICAR was shown to dose-dependently inhibit 
fructose-1,6-bisphosphatase activity hence potently inhibiting gluconeogenesis. 
Consequently, to circumvent this lack of specificity, Cool et al., identified a 
thienopyridone family of AMPK activators [278]. The authors show that A-769662 
directly stimulated partially purified rat hepatic AMPK (EC50 = 0.8 µM) and inhibited 
fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 µM). Furthermore, treatment 
of ob/ob mice with 30 mg/kg A-769662 decreased hepatic expression of PEPCK, 
G6Pase, and FAS, lowered plasma glucose by 40%, reduced body weight gain and 
significantly decreased both plasma and hepatic triglyceride levels. However, the 
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molecular mechanisms underlying AMPK activation by A-769662 are presently 
unknown, but this compound remains a putative AMPK activator that may be used in 
vivo. 
Leclerc and coworkers showed that treatment of rat hepatocytes with AICAR decreases 
HNF4α protein stability and consequently decreases the expression of some of its target 
genes. The authors claimed that AMPK phosphorylates HNF4α, thereby reducing its 
homodimerization and DNA-binding activities and stimulating its degradation, resulting 
in down-regulation of HNF4α target genes [279]. This is not consistent with the 
possibility of AMPK regulating drug induction by increasing the HNF4α expression or 
activity, but it corroborates the role of AMPK in the regulation of PEPCK. 
Another potential target of AMPK in the regulation of gluconeogenesis is p300, a 
transcriptionnal coactivator with strong histone acetyltransferase activity, which acts not 
only as an adaptor between basal transcription machinery and transcription factors, but 
also plays a role in the acetylation of histones in order to increase DNA accessibility, or, 
other proteins for their activation, nuclear retention or modulation of half-life. AMPK 
phosphorylates p300, reducing its ability to bind to nuclear receptors and thus repressing 
their target gene expression [280]. As previously mentioned, p300 is simultaneously 
recruited together with CREB-binding protein (CBP) to the PEPCK promoter during 
fasting to activate gluconeogenesis [281]. Although, the AMPK-mediated 
phosphorylation of p300 has never been demonstrated under fasting conditions, p300 
remains a potential downstream target of AMPK in the repression of PEPCK. 
Another group showed that a dual specificity phosphatase, DUSP-4, is induced by AMPK 
in H4IIE and Fao hepatoma cells at both mRNA and protein levels [282]. The authors 
also demonstrated that AMPK induces the immediate early transcription factor EGR-1 
(early growth response 1), a known transcriptional activator of DUSP-4, and it directly 
binds the DUSP-4 promoter at its known binding site. Consequently, the activation of 
dusp-4 leads to the inhibtion of PEPCK and G6Pase but the mechanistic part of this study 
remains uncomplete. Furthermore, the in vivo importance of EGR1 and DUSP-4 
activation in gluconeogenesis remains to be addressed. 
The forkhead transcription factor FKHR (now referred to as FOXO1) [283], a known 
positive regulator of PEPCK has also recently been shown to be down-regulated upon  
AICAR incubation in H4IIE hepatoma cells [284]. Lower expression of this factor may in 
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turn repress G6Pase and PEPCK genes [205]. However, as previously mentioned, the 
data obtained with AICAR should be interpreted with caution as its specificity in the 
activation of AMPK is limited. Furthermore, the studies never demonstrated the 
phosphorylation of FOXO1 by AMPK neither in vitro nor in vivo.  
In addition to gluconeogenesis, AMPK has been implicated in the regulation of hepatic 
lipogenesis, lipid oxidation, and cholesterol synthesis [285]. AMPK suppresses glucose-
induced expression of lipogenesis-associated genes such as fatty acid synthase [286], 
ACC, and pyruvate kinase [287]. In rat primary hepatocytes, activation of AMPK by 
AICAR or metformin increases fatty acid oxidation by inhibiting ACC [286]. 
Consistently, in rats treated with metformin, triglyceride levels are reduced, 
concomitantly with an increase in β-hydroxybutyrate, suggesting elevated hepatic lipid 
oxidation [286]. These enhanced metabolic profiles are accompanied by downregulation 
of lipogenic genes such as SREBP-1, fatty acid synthase, and S14 [286]. Moreover, the 
lipid-lowering effects of metformin in cultured hepatocytes requires AMPK activity 
[288]. Taken together, these studies provide evidence that AMPK suppresses hepatic 
gluconeogenesis and lipid production, while decreasing hepatic lipid deposition by 
increased lipid oxidation, thus improving the glucose and lipid metabolism in type-2 
diabetes. 
A perplexing aspect of the role of AMPK in the normal regulation of hepatic gene 
expression is that changes in the activity of the enzyme have been difficult to measure in 
primary isolated hepatocytes, under conditions in which alterations in lipogenic and/or 
gluconeogenic gene expression are clearly evident [287, 289]. Moreover, while 
expression of a constitutively active form of AMPK α1 completely abrogated the effects 
of glucose on the levels of mRNAs encoding lipogenic enzymes, inhibition of AMPK 
activity with dominant-negative AMPK α1 failed to alter the suppression of these genes 
by low glucose concentrations [287]. Thus active AMPK would appear to serve in the 
liver as an efficient silencer of lipogenic gene expression, and this role may be important 
in mediating the effects of fatty acids during starvation [290]. On the other hand, it seems 
likely that additional mechanisms are involved in the normal stimulatory action of high 
glucose (and insulin) on hepatic expression of lipogenic genes. 
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Figure 4:  Transcriptional control of gluconeogenesis by TORC2 and AMPK  
The activity of TORC2 is controlled by AMPK phosphorylation, which determines whether TORC2 becomes localized in the nucleus. Phosphorylated TORC2 is 
sequestered in the cytoplasm via a phosphorylation-dependent interaction with 14-3-3 proteins. Moreover, AMPK can also control gluconeogenic gene transcription 
by regulating stability or degradation of HNF4α and FoxO1 transcription factors. 
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Regulation of gluconeogenesis in diabetes 
Type-2 diabetes is characterized by peripheral insulin resistance associated with chronic 
hyperglyceamia notably due to a gradual and progressive increase in endogenous glucose 
production during fasting. In the fasted state, gluconeogenesis is increased in diabetic 
compared with normal individuals and is incompletely suppressed by insulin in the 
postprandial state [291]. Thus, increased hepatic glucose production contributes to 
hyperglycemia in both the fasting and postprandial states. High-level expression of the 
PEPCK-C gene in the liver is a major characteristic of diabetes. Additionally, transgenic 
mice containing multiple copies of the rat PEPCK-C gene display hyperglyceamia that is 
resistant to insulin [292], strongly suggesting that overproduction of PEPCK itself can 
disrupt glucose homeostasis and subsequently lead to diabetes. Furthermore, mice 
carrying tissue-specific deletion of PEPCK or overexpressed PEPCK displayed type-2 
diabetes phenotype, as well as several unexpected phenotypes such as obesity, 
lipodystrophy, fatty liver, and death. These phenotypes arise from perturbations not only 
in gluconeogenesis, but in two additional metabolic functions of PEPCK-C: first, 
cataplerosis [293], which maintains metabolic flux through the Krebs cycle by removing 
excess oxaloacetate, and second glyceroneogenesis, which produces glycerol-3-phosphate 
as a precursor for fatty acid esterification into triglycerides [294]. PEPCK-C catalyzes the 
conversion of oxaloacetate to phosphoenolpyruvate. It is in part the tissue-specificity of 
this simple reaction that results in the variety of phenotypes listed above. Mice with a 
total knockout of PEPCK die within 2-3 days from birth, not from hypoglycemia, but 
probably because the Krebs cycle slows to approximately 10% of normal level in the 
absence of cataplerosis [295].  
However, Burgess et al. recently demonstrated that 90% reduction of PEPCK content in 
the liver causes 40% reduction in gluconeogenic flux, indicating a lower capacity for 
PEPCK protein to control gluconeogenesis than expected [296]. This result suggests that 
other factors such as peripheral substrate supply or insulin-mediated effects on other 
gluconeogenic enzymes and/or hepatic energy metabolism must coordinate with PEPCK 
expression to attenuate gluconeogenesis. Although, liver-specific PEPCK knockout mice 
have markedly impaired hepatic gluconeogenesis, they are able to maintain a near-normal 
blood glucose concentration during fasting by increasing extrahepatic gluconeogenesis 
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and diminishing whole-body glucose utilization [297]. Furthermore, variety of studies in 
mice demonstrate important modulations of hepatic glucose metabolism even in the 
absence of altered PEPCK expression [298, 299] or disregulated PEPCK expression 
without significant effect on gluconeogenesis [300]. This incongruence might occur 
because other factors, such as hepatic energy metabolism [301], can also project 
substantial control over the rate of gluconeogenesis. Moreover, sustained induction of 
PEPCK may also occur as an indirect consequence of the decrease in glucose tolerance in 
diabetes. This is also favors an efficient cooperation between different factors, all 
involved in intricated pathways that control the endogenous glucose production. 
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Concluding remarks 
Phenobarbital was found to repress genes that encode enzymes involved in 
gluconeogenesis such as phosphoenolpyruvate carboxykinase (PEPCK). Here, we show 
that both CAR and AMPK are necessary to mediate the PB inhibitory effect on PEPCK 
mRNA expression. Furthermore, our study indicates that AMPK and CAR interacts in the 
regulation of PEPCK promoter activity. Once activated by PB, the CAR-AMPK complex 
may prevents coactivators such as PGC-1α from their recruitment to the PEPCK 
promoter. Whether the physiological objective of PEPCK repression consists in the 
prevention of NADPH loss remains to be evaluated. NADPH is essential for cytochrome 
P450 dependent monoxygenase activities and glutathion recycling. In the liver, the 
pentose phosphate pathway converts glucose 6-phosphate to ribose 5-phosphate by 
glucose 6-phosphate dehydrogenase (G6PDH) and generates NADPH. In the 
gluconeogenesis pathway, glucose 6-phosphate is the last intermediate on the way to 
glucose, a reaction catalyzed by G6Pase. Thus, repression of gluconeogenesis by 
xenobiotic-activated CAR might be required to maintain sufficient NADPH levels for 
xenobiotic metabolism. Alternatively, the decrease in CAR/PXR activity by insulin is 
consistent with decreased NADPH production through repression of gluconeogenesis. 
On the other hand, we demonstrate that endogenous CAR positively regulates PEPCK 
and the expression of genes encoding for of acetyl-CoA carboxylase (ACC), an enzyme 
known to be involved in the conrtol of lipogenesis and beta oxidation of fatty acids. 
Although, pharmacological activation of CAR by PB may not necessarily reflects the 
constitutive endogenous activation of CAR, the activation of AMPK by PB and the 
subsequent interaction between CAR and AMPK provide a strong link between energy 
and drug metabolism. This is also consistent with a hypothesized protection of NADPH 
stocks. Therefore, the CAR-AMPK connection may serves as an energy sensing platform. 
In response to nutritional stress or to xenobiotics, the connection may recruits specific 
cofactors to permanently control the energy status of the cell, suggesting that CAR might 
be an energy sensor too. 
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Outlook 
Phenobarbital is an excellent pharmacological tool in the comprehension of the molecular 
mechanisms underlying CAR function in the liver. Since cDNA microarray experiments 
revealed that more than 140 genes are regulated by PB and CAR regulates only half of 
them, it is clear that CAR is not the limiting factor mediating the entire phenobarbital 
effect in the liver. On the other hand, independently of its activation by PB endogenous 
CAR plays a role in glucose homeostasis even though CAR’s precise function in glucose 
turnover remains unknown. It would be very interesting to measure glucose disposal, 
production and blood basal parameters such as glyceamia, insulinemia, triglycerideamia 
and total cholesteroleamia in CARKO mice injected with streptozotocin, a drug that 
destroys pancreatic cells thereby leading to diabetes. Moreover, it would be very 
attractive to see whether the suppression of CAR mRNA expression or the inhibition of 
its activity in db/db and ob/ob diabetic mice would improve the hyperphagia, 
hyperglyceamia, hyperlipidemia and obesity in these animals. Furthermore, as we 
previously suggested, CAR may also be involved in the regulation of lipogenesis and/or 
the beta oxidation of fatty acids in the liver, and since these animals are resistant to 
hepatic steatosis we might speculate that CAR may indirectly regulate energy 
expenditure. Consequently it would be useful to measure the ability of CARKO animals 
to run on a wheel and to measure their respiratory quotient.  
To evaluate the physiological relevance of the AMPK-CAR connection it would also be 
of interest to generate animals with liver-specific deletion of both AMPKα1/2 subunit 
and CAR. Additionally, AMPK activity should be assessed in livers of CARKO mice, 
under different nutritional conditions. Unlike the classic model of nuclear receptor action 
in which a receptor only directly binds to its enhancer element, CAR also exerts its effect 
by acting as a co-regulator of gene transcription. The specificity of CAR activity may be 
dependent on the specificity of the interaction with a cofactor including PGC-1α and 
SRC-1. Thus, the identification of CAR new partners in a particular physiological 
context will certainly help in the comprehension of the molecular mechanisms underlying 
CAR function in drug metabolism and in energy metabolism. 
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Materials and Methods. 
 
Reagents 
Phenobarbital (sodium salt) was purchased from Fluka (Buchs, Switzerland). All other 
chemicals were from Sigma (Buchs, Switzerland). Cell culture media, foetal bovine 
serum, other tissue culture reagents, and Trizol reagent were from Gibco-BRL Life-
Sciences Basel, Switzerland. Antibodies rose against AMPK α1 and α2 subunits and 
phospho-acetyl-CoAcarboxylase were purchased from Upstate Biotechnology (Lucern, 
Switzerland). 
 
Plasmid constructs 
The eukaryotic expression plasmid for human CAR has previously been described [187]. 
The proximal promoter of the rat PEPCK-CAT (–467 to +69, with respect to the 
transcription start site), was described and kindly provided by Dr Granner. PEPCK-CAT 
was digested with AflIII and BglII and subcloned into the digested luciferase reporter 
gene vector pGL3-Basic (Promega). 
 
Transient Transfections and Reporter Gene Assays 
Transactivation assays with CV-1 cells were performed as previously 
described.(Handschin et al., 2000) CV-1 cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum 
(Sigma, Buchs, Switzerland). Cells were split 1:10 in DMEM/F12 without phenol red 
(Invitrogen), supplemented with 10% charcoal-stripped fetal bovine serum. After 3 days' 
incubation, cells were plated in 96-well plates at a density of 30,000 cells per well and 
expanded overnight. The medium was then replaced with the transfection mixes in 
Optimem I without phenol red (Invitrogen). Transfection mixes contained 10 ng of 
expression construct encoding either human  CAR cDNA (kindly provided by Dr M. 
Negishi, National Institute of Environmental Health Sciences, Research Triangle Park, 
NC) or 50 ng of human PGC-1α, (kindly provided by Dr A. Kralli, Departments of Cell 
Biology, The Scripps Research Institute, La Jolla, California), 20 ng of reporter vector 
PEPCK-LUC containing the -467+69 fragment of the rat PEPCK promoter; 60 ng of 
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pRSV- β -galactosidase construct; and carrier plasmid to a total of 150 ng 
deoxyribonucleic acid per well. Cells were transiently transfected with 1 µL/well of 
Lipofectamine reagent (Invitrogen) according to the manufacturer's protocol. After 
overnight incubation, medium was replaced with DMEM/F12 without phenol red, 
supplemented with 10% delipidated, charcoal-stripped fetal calf serum (Sigma, Buchs, 
Switzerland) containing the inducer compounds of interest dissolved in dimethylsulfoxide 
vehicle at a final concentration of 0.1%. After 24 hours' incubation, cells were lysed in 
Passive Lysis Buffer (Promega, Madison, Wis). Luciferase and β-galactosidase activities 
were determined as previously described [27]. 
 
Generation of AMPKα1/α2 LS-/- knock out mice. 
The liver-specific knock out of both alpha subunits of AMPK has previously been 
described [302]. Briefly, to generate deletion of both catalytic subunits in the liver (α1α2 
LS-/- ), liver specific AMPKα2-null mouse were first generated by crossing floxed 
AMPKα2 mice (Viollet et al.,2003) and Alfp Cre transgenic mice expressing the Cre 
recombinase under the control of albumin and α-fetoprotein regulatory elements. A liver-
specific AMPKα2 deletion was then produced on an AMPKα1 -/- general knock out 
background by crossing liver-specific α2-/- mice with AMPKα1-/- general knock out 
mice [303]. 
 
Generation of CAR knock out mice 
The targeted deletion of the nuclear constitutive androstane receptor (CAR) in mice has 
previously been described [30]. Breeding pairs of these CAR knock out mice were kindly 
provided by David D. Moore (Department of Biochemistry and Molecular Biology, 
University of Texas Medical School of Houston, Texas USA). 
 
Recombinant adenoviruses 
Adenovirus expressing Hemagglutinin tagged human CAR (Ad-HAhCAR) was 
constructed by using Gateway cloning and the ViraPower Adenoviral Expression System 
(both from Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. 
First, the 2560-bp cDNA fragment encoding the human CAR cDNA and a CMV 
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promoter was sub-cloned by PCR from a pCIneo-hCAR contruct into the pDONOR 
Gateway vector by the following homologous recombination oligonucleotides: 
5’-
GGGGACAGTTTGTACAAAAAAGCAGGCTGCTCACCATGGCTCGACAGATCT-
3’ and 5’-
GGGGACCACTTTGTAACAAGAAAGCTGGGTTTACGCCAGCCCGATCCTT-3’. 
The construct was then transferred into the pAdDEST adenoviral Gateway vector by LR 
Clonase (Invitrogen) reaction to give pAdHAhCAR. Integrity and proper insertion of the 
cloned hCAR cDNA were confirmed by sequencing. Adenoviral expression plasmids, 
pADEST and pDONOR, and packaging plasmid mix were purchased from Invitrogen 
(Invitrogen, Carlsbad, CA). Production of adenoviral particles and subsequent infection 
of target cells were performed essentially according to the manufacturer's protocols, 
except that Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was used for transfection of 
HEK-293T packaging cells. Pseudoviral supernatant harvested from the packaging cells 
was used directly for cell infection. 
Adenovirus encoding constitutively active α1 AMPK subunit (ad-CA-α1 312) or 
dominant negative mutant α1 AMPK (ad-DNα1) were prepared as described (Diraison et 
al.,2004). Adenoviruses encoding constitutively active α2 AMPK subunit (ad-CA-α2 
312) or β-galactosidase were also amplified as previously described (Foretz et al.,2005). 
Adenovirus encoding human CAR in fusion with eGFP (ad-hCAR-GFP) was a kind gift 
of Dr Ramiro 
Jover (Hospital La Fe, Valencia, Spain). AMPK adenoviruses also express enhanced 
green fluorescence protein (eGFP), under control of a distinct CMV promoter. 
  
Culture of primary human hepatocytes. 
Cultures of primary human hepatocytes were obtained from patients undergoing liver 
surgery. All patients gave written consent. Culture from 3 donors were prepared and 
plated as described [64]. The cultures were maintained 24h in serum free induction 
medium (William’sE (invitrogen, Basel Switzerland) supplemented with 0.5x ITS 
(Insulin transferrin Selenium) and 100 nM hydrocortisone (both Sigma, Buchs, 
Switzerland), when medium was changed and cultures were exposed to chemicals as 
indicated in the figure legends. 
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Preparation and culture of primary mouse hepatocytes. 
Liver cells were prepared by the two step collagenase method (Berry and Friend,1969) 
from post-absorptive male mice (25-30g) after anaesthesia with ketamin/xylazin (1 
mg/100 g body weight). Cell viability (>80%) was checked by trypan blue exclusion. 
Hepatocytes were seeded on rat tail collagen type1 coated dishes and cultured overnight 
in DMEM supplemented with 50 U/ml penicillin, 50 µg/ml streptomycin. After overnight 
culture, the medium was replaced by a serum free DMEM medium. Twelve hours after 
serum deprivation cells were exposed to chemicals for 8 hours or as indicated in the 
figure legends, and were maintained in serum free medium. 
 
Real-time PCR assays 
One µg of total RNA was reverse-transcribed and used in real-time PCR assays for 
quantification of different target genes on an ABI PRISM 7700 sequence detection 
system. Expression levels of these genes were normalized against 18s rRNA for human 
samples and normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA for mouse samples. The primer sequences are described in table 1. 
 
Western blot analysis 
Cultured hepatocytes were washed in ice cold PBS and harvested in 300 µl/6-cm dish of 
extraction buffer (KCl 100 mM, Hepes 25 mM, MgCl2 7.5 mM, glycerol 20%, pH 7.4, 
supplemented with protease inhibitors cocktail tablets (Roche, Rotkreuz, Switzerland) 
containing dithiothreitol (4 mM), aprotinin (2 mg/ml) and ß-mercaptoethanol (1 mM). 
The cell suspension was sonicated for 5 sec and cellular debris removed by centrifugation 
(1000xg for 10 min at 4°C). Thirty micrograms of total cellular protein were separated by 
Tris-Tricine glycerol-SDS PAGE and blotted onto nitrocellulose membranes. The 
following primary antibodies were employed: anti-AMPK α1 subunit and anti-AMPK α2 
subunit, anti-phospho-ACC (Cell Signalling, Allschwill, Switzerland) and anti-Myc 
(clone 9E10) (Sigma, Buchs, Switzerland). Secondary antibodies anti-rabbit IgG and 
anti-mouse IgG conjugated to horseradish peroxidase were employed for 
chemiluminescence immunodetection. Blots were developed using ECL reagent 
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(Amersham Biosciences, Otelfingen, Switzerland) and exposure to  Kodak X-ray films 
(Sigma, Buchs, Switzerland). 
Immunoprecipitation. 
mAT3F cells were cultured in DMEM F12 medium (Gibco, Chagrin falls, ohio) 
supplemented with penicillin streptomycin, 0.1 uM insulin, 1uM dexamethasone and 5% 
fetal bovine serum (Lefrancois-Martinez AM. Et al., 1994). The cells were co-infected 
with HA-hCAR and Myc-AMPKα1/2 adenoviruses for 48 h and were treated with PB or 
dexamethasone/cAMP for 1 hour. The cells were scraped in Tris 500 mM pH7.5, NaF 
500 mM, EDTA 10 mM, EGTA 10 mM, Mannitol 2.5 M, 5 % Triton X-100, phosphatase 
inhibitor cocktail I and II (Sigma, Buchs, Switzerland) and protease inhibitors (Roche, 
Switzerland) left 15 min on ice, vortexed for 5 s, and centrifuged for 10 min at 4°C and 
20,800 x g. A BCA assay was used to determine the protein content of the supernatant. 
The HA antibody (Covance, USA) and the myc antibody (Sigma, Buchs, Switzerland) 
were added to 500 ug of proteins and rotated overnight at 4°C. Finally, protein G agarose 
beads were rotated with lysates and antibodies for 2h at 4°C. The beads were washed 
three times with PBS before being resuspended in protein loading buffer. 
 
Immunocytochemistry. 
Hepatocytes were cultured on glass coverslips coated with rat-tail collagen (25µg/cm2). 
Human hepatocytes were infected 12 h after seeding in a serum-free medium with Ad-
hCAR-GFP at an MOI of 30 to 100. Endogenous AMPK α2 was detected with polyclonal 
antibody (abcam) and a secondary antibody Alexafluor 594 (Molecular probes).Twelve 
hours after infection, cells were exposed to chemicals for 6 h then washed twice at room 
temperature with PBS and fixed for 20 min in 4% (w/v) paraformaldehyde. Cells were 
visualized in Mowiol mounting medium with a 40x objective (1.40 numerical apertures) 
by using a Leica TCS NT confocal laser scanning microscope (Leica, Wetzlar, Germany).  
 
Mammalian two hybrid assay 
An expression plasmid for GAL4 DNA binding domain (Gal4RE) fused to human CAR 
ligand binding domain (hCAR LBD) was constructed [304]. This plasmid was 
cotransfected in CV-1 cells with psG5-hPGC-1α or pCDNA3-AMPK α2 and the reporter 
plasmid pGal4 response element-Luc. Luciferase was determined as described above. 
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Glucose production 
Primary mouse hepatocytes were serum-starved overnight and stimulated with insulin 
(100 nm) for 24 h. Cells were washed and incubated in DMEM glucose free medium 
containing 20 mM lactate and 2 mM pyruvate for 24 h. Culture medium was collected 
and centrifuged, and glucose levels were determined by glucose-oxidase kit, according to 
the manufacturer instruction (Sigma-Aldrich) and normalized to protein content of the 
cells. 
 
Immobilized metal affinity chromatography (IMAC) 
One microgram of recombinant his-AMPKα1 subunit (cell signaling) was incubated for 
1h at 4°C, in HEPES 50mM pH 7.5, NP140 0.1%, glycerol 10%, KCl 1mM, MgCl2 2mM 
with 200 µg of protein lysate from human hepatocytes previously infected with HAhCAR 
adenovirus. The histidine tagged complex was retained on a Nickel affinity gel (Sigma, 
Buchs, Switzerland). The complex was washed and eluted with imidazole according to 
the manufacturer instructions. The different fraction were analysed on 10% SDS PAGE 
 
AMPK activity measurement 
AMPK activity was measured using the SAMS peptide (HMRSAMSGLHLVKRR) 
phosphorylation assay kit from Upstate biotechnology (Luzern, Switzerland) according to 
the manufacturer’s instructions. Briefly, a soluble fraction containing active AMPK is 
used in a 40 ul reaction in the presence of 75 mM MgCl2, 0.5 mM ATP, 0.3 mM AMP, 
0.1 mM SAMS, 0.4 mM DTT and 1 mCi/100 ul [γ-32P] ATP for 10 min at 30°C. At the 
end of the incubation, 35 ul of supernatant from the reaction mixture were spotted on 
Whatmann filter papers (P81) which were then washed three times with 0.75% 
phosphoric acid, once with acetone and then allowed to by dried befor scintillation 
counting in 5 ml scintillation cocktail. 
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Animals 
C57/B6 wild-type mice and mice with a targeted deletion of the nuclear constitutive 
androstane receptor were maintained on a standard laboratory chow with food and water 
ad libitum. Twelve week-old male mice from each genotype were grouped in 4 to 6 
animals and were previously injected by phenobarbital 50 mg/kg for 10h. The animals 
were then fed and fasted as described in the legends of the figures. 
Some mice have been refed upon a high carbohydrate-low fat diet. The composition of 
theses pellets is: 
 
Saccharose 75 % 
Pork fat 3 % 
Protein 13.5 % 
Calories 15.2 MJ/kg 
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Abbreviations 
 
ACC    acetyl-CoA carboxylase 
AF2   accessory factor 2 
AICAR   5’-phosphoribosyl-5-aminoimidazol-4-carboxamide 
ALAS1   d-aminolevulinic acid synthase 1  
ATP   adenosuine monophosphate 
AMPK   AMP-activated protein kinase  
AREBP  AICAR response element binding protein 
ATP   adenosine triphosphate 
BAs   bile acids 
bp   basepair(s) 
CAR    constitutive androstane receptor 
CaMK    calcium/calmodulin-dependent protein kinase 
CCRP   cytoplasmic CAR retention protein 
C/EBP α  CCAAT/enhancer-binding protein 
CITCO 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-
(3,4-dichlorobenzyl)oxime 
CREB   cAMP response element binding protein 
CREM   cAMP response element modulator 
CRU   cAMP response unit 
CPT   carnitine palmitoyl transferase I 
CXR    chicken xenobiotic receptor  
CYP    cytochrome P450 
DBD   DNA-binding domain  
DN   dominant negative 
DR   direct repeat 
DUSP-4  dual specific phosphatase-4 
EGFP   Enhanced green fluorescent protein 
EGP   Endogenous glucose production 
EGR1   Epidermal growth factor receptor 1 
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ER   everted reapeat 
FOXO1  forkhead box protein O1A 
FXR   farnesoid X receptor 
G-6-Pase  glucose 6-phosphatase 
GAPDH  glyceraldehydes-3-phosphate dehydrogenase 
GK   glucokinase 
GLUT    glucose transporter 
GR   glucocorticoid receptor 
GRU   glucocorticoid response unit 
HNF4α  hepatocyte nuclear factor 4α 
Hsp90   heat shock protein 90 
IF   immunofluorescence 
IL-6   interleukine 6 
IP   immunoprecipitation 
IR   inverted repeat 
IRE   insulin response element 
IRS   insulin response sequence 
kDa   kilodalton(s) 
LBD   ligand-binding domain  
LMH   leghorn male hepatoma 
LXR   liver X receptor  
MDR1   multidrug resistance gene 1 
miRNA  micro RNA 
MRP2   multidrug resistance-associated protein 2 
NFkB   nuclear factor kappaB 
NADPH  nicotinamide adenine dinucleotide phosphate 
NIDDM  Non-insulin dependent diabetes 
NOS   nitric oxide synthase 
NR   nuclear receptor 
OA   okadaic acid 
OATP2  organic anion transport protein 2 
PAGE    polyacrylamide gel electrophoresis 
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PB    phenobarbital  
PBP   PPAR-binding protein 
PBREM  phenobarbital-responsive enhancer module 
PBRU   phenobarbital-responsive enhancer unit 
PCN   5-pregnen-3b-ol-20-one-16a-carbonitrile 
PCR   polymerase chain reaction 
PEPCK  phosphoenolpyruvate carboxykinase 
PGC-1α  peroxisome proliferator-activated receptor gamma coactivator α 
PKA   cAMP-dependent protein kinase A 
PP2A   protein phosphatase 2A 
PPAR   peroxisome proliferator-activated receptor 
PXR    pregnane X receptor  
RT-PCR   real-time PCR  
RAR   retinoic 
RXR   9-cis-retinoic acid receptor 
siRNA   small interfering RNA 
SREBP-1c  sterol response element binding protein-1c 
SULT   sulfotransferase 
TCPOBOP  1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene 
TNFα   tumor necrosis factor α    
TORC   Transducer of regulatory CREB 
TR   thyroid hormone receptor 
TSH   thyroid stimulating hormone 
UCP-1   uncoupling protein 1 
UGT   UDP-glucuronosyltransferase 
5’ UTR  5’ untranslated region 
VDR   vitamin D receptor 
XLS   xenobiotic localization signal 
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